Brigham Young University

BYU ScholarsArchive
Theses and Dissertations
2016-03-01

Discovery of Low-Molecular Weight Novel Serum Biomarkers for
Diagnosing Preeclampsia and Alzheimer's Disease
Swati Anand
Brigham Young University

Follow this and additional works at: https://scholarsarchive.byu.edu/etd
Part of the Chemistry Commons

BYU ScholarsArchive Citation
Anand, Swati, "Discovery of Low-Molecular Weight Novel Serum Biomarkers for Diagnosing Preeclampsia
and Alzheimer's Disease" (2016). Theses and Dissertations. 6200.
https://scholarsarchive.byu.edu/etd/6200

This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for
inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more
information, please contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.

Discovery of Low-Molecular Weight Novel Serum Biomarkers for Diagnosing Preeclampsia and
Alzheimer’s Disease

Swati Anand

A dissertation submitted to the faculty of
Brigham Young University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy

Steven W. Graves, Chair
David V. Dearden

Daniel E. Austin
John C. Price
John D. Lamb

Department of Chemistry and Biochemistry
Brigham Young University
March 2016

Copyright © 2016 Swati Anand
All Rights Reserved

ABSTRACT
Discovery of Low-Molecular Weight Novel Serum Biomarkers for Diagnosing
Preeclampsia and Alzheimer’s Disease

Swati Anand
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Preeclampsia (PE), a life threatening pregnancy-related disorder, is characterized mainly
by new onset of hypertension and proteinuria after 20 weeks of gestation. Currently, PE cannot be
predicted prior to onset of symptoms and there is no cure for the disease. There is a clear value in
having biomarkers able, early in a pregnancy, to identify women at risk for PE so that proper
treatment therapies could be developed. Although a number of serum candidate markers have been
proposed to be altered in PE patients, their use is limited due to poor sensitivity and specificity.
Therefore, there is ongoing need for better set of novel biomarkers predicting PE.
Consequently, for my first project, we used a serum proteomic approach involving reversed
phase capillary-liquid chromatography-electrospray ionization-quadrupole-time of flight mass
spectrometry (cLC-ESI-QTOF). Our approach focuses on the less abundant (nM or lower), lower
molecular weight peptides and lipids predicting PE. We got previously collected sera from
pregnant women at 12–14 weeks gestation. There were 24 controls, having term uncomplicated
pregnancies and 24 cases, which developed PE later in the same pregnancy. Many statistically
significant serum PE biomarker candidates were found comparing cases and controls. In addition,
multimarker combinations having high detection sensitivity and specificity (AUC >0.9) were
developed using logistic regression analysis.
For my second project, serum lipidomic analysis of sera from pregnant women was
undertaken to determine if useful PE lipid biomarkers exist. A discovery study involving a shotgun
lipidomic approach was performed using sera collected at 12-14 weeks of pregnancy from 27
controls with uncomplicated pregnancies and 29 cases that later developed PE. Lipids were
extracted using organic solvent and analyzed by direct infusion into a time-of-flight mass
spectrometer. Statistically significant lipid markers were found and reevaluated in a second
confirmatory study having 43 controls and 37 PE cases. The initial study detected 45 potential PE
markers. Of these, 23 markers continued to be statistically significant in the second confirmatory
set. Several multi-marker panels with AUC >0.85 and high predictive values were developed from
these markers.
My third project also involved the above mentioned approach for detection of novel lipid
biomarkers for Alzheimer’s disease. Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder and the most common cause of age-related dementia. Currently, there are no methods to
detect Alzheimer’s at an early stage when treatment therapies could be applied. Therefore, there is
need for detection of panel of biomarkers for detecting patients at risk to AD at an early stage. In
the initial discovery set, sera from 29 different stage AD cases and 32 controls were analyzed using

direct infusion mass spectrometry (ESI-TOF). This study yielded 89 potential lipid biomarkers
which were evaluated in another confirmation study. Of these, 35 markers continued to be
statistically significant in the second confirmatory set. Using the confirmed markers, several multimarker panels with AUC > 0.87 were developed for any stage AD cases vs controls. Multi-marker
panels with AUCs > 0.90 were developed for each specific CDR vs controls, including the earliest
stage of AD. These lipidomic biomarkers are likely to distinguish AD cases regardless of the stage
from controls.
In conclusion, we successfully detected, validated and identified low molecular weight
novel biomarkers for PE and lipid biomarkers for AD.

Keywords: Preeclampsia, Alzheimer’s disease, Proteomics, Lipidomics, Mass spectrometry, diagnosis,
biomarkers
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Chapter 1

-Introduction

1.1

Electrospray Ionization-Quadrupole-Time-Of-Flight Mass Spectrometer (ESIQqTOF)
During the latter half of the twentieth century mass spectrometers (MS) have played a significant
role in measuring and identifying biological species used for clinical diagnosis

1-2

. This was

because of their high resolution, sensitivity, mass accuracy, dynamic range and tandem MS
abilities. We used a quadrupole-time of flight (QqTOF) mass spectrometer having an electrospray
ionization source (ESI) for our studies described below.

1.1.1 QqTOF
Although first commercially introduced in 1996, QqTOF-MS have evolved over the years in terms
of improved mass accuracy and resolving power and tandem MS abilities. Q is a mass resolving
quadrupole; q refers to radio frequency (r.f.) only quadrupole or collision cell and TOF-MS refers
to a time-of-flight mass spectrometer. The complete setup is shown in Figure 1.1 3. The instrument
also has an additional r.f. only quadrupole q0 to provide collisional damping. Therefore, it consists
of three quadrupoles q0, q1 and q2 where q0 and q2 are operated in r.f only mode to provide
confinement of the ions. Both q0 and q2 are operated at several millitorr gas pressue to allow
collision of specimen ions with neutral gas molecules like nitrogen or argon effectively resulting
in collisional damping and ion focusing. It reduces both the energy and directional spread of ions
leading to better transmission.

1

Figure 1.1 Quadrupole time-of-flight mass spectrometer.
(Taken from Chernushevich, Igor V., Alexander V. Loboda, and Bruce A. Thomsoken from. T "An
introduction to quadrupole–time‐of‐flight mass spectrometry." Journal of Mass Spectrometry 36.8
(2001): 849-865.)
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For MS1 experiments, Q1 is mainly operated in r.f. mode acting as an ion transmission source,
while TOF is used for recording the spectra because of its high resolution, mass accuracy and
ability to simultaneously record ions without scanning, resulting in faster analysis.
In MS/MS, Q1 acts as a mass filter selecting a parent ion of interest. Therefore, Q1 is operated at
very low pressures ~10-5 torr to successfully isolate the ion of interest. The selected ion is then
accelerated at a specified energy before it enters the collision cell where it undergoes collisions
with the neutral gas molecules and is fragmented into product ions.
When the quadrupole is used as a mass analyzer, both r.f. and d.c. voltages are applied to the
rods. Mathieu parameters qM and aM are used to characterize the amplitudes of both the voltages
qM =

4𝑒𝑉

aM =

𝑚
𝑧

( )ὠ2 𝑟 2

8𝑒𝑈
𝑚
𝑧

( )ὠ2 𝑟 2

where, e represents the charge of an electron, V and ὠ are the amplitude and angular frequency of
the r.f. voltage. U is the amplitude of the d.c. voltage and r is the radius of the quadrupoles.
In general, transmission of ions having very high m/z is compromised as the effective potential is
inversely proportional to the m/z.
After leaving the collision cell, the ions are reaccelerated at the given energy, followed by focusing
the ion optics into the ion modulator region of the linear TOF. When leaving the acceleration
region, all the ions should possess the same kinetic energies while entering the field free drift tube.
Because the kinetic energies for all the ions are same, their velocities are inversely proportional to
their masses resulting in the lighter ions reaching the detector faster than the heavier ions. The
flight time (tF) is given by

3

𝐿

𝑚

tF = 𝑣 = L√2𝑧𝑒𝑉
Where L is the distance from the source to the detector, ν is velocity, m is mass, z is charge and V
is the acceleration voltage.
A reflector/reflectron time-of-flight analyzer consists of a series of electrodes at the end of the
field-free region at high potential. The voltage of the reflectron is higher than the acceleration
voltage. This results in the effective penetration of all the ions until they reach zero kinetic energy
(KE). The ions having high KE penetrate deeper and spend more time as compared with the ones
having lower KE. The ions are then expelled by the reflectron and their kinetic energies remain
unchanged. The ions in increasing order of their kinetic energies finally reach the detector. The
reflector TOF analyzer allows for correction in time-of-flight as well as spatial spread and angular
spread resulting in improved resolving power as compared to a linear TOF analyzer.
The orthogonal acceleration TOF (oa-TOF) analyzer results in the transmission of ions orthogonal
to their initial direction due to application of the pulsed electric field across the modulator region.
The ions acquire kinetic energy and enter the field-free region where TOF mass separation occurs.
The ratio of the velocities (or energies) in the acceleration region and orthogonal region decides
the order of the ions reaching the ion mirror, from where the ions are directly deflected to the
detector. The ion mirror compensates the energy and spatial spread of the ions.
The oaTOF offers several advantages including high mass resolving power, sensitivity, spectral
acquisition rate and mass accuracy.
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1.1.2 Electrospray ionization (ESI)
ESI is a soft ionization technique first reported in 1984 4. It allows the formation of multiply
charged species which allows detection of very large analytes. It takes place at atmospheric
pressure and can be coupled to liquid chromatography resulting in the separation of complex
mixtures before entering the MS. Analyte solutions are transferred through a metal capillary needle
which is maintained at several kV (2-6 kV) with respect to a cylindrical electrode resulting in spray
of charged droplets. A coaxial flow of sheath gas (dry N2) around the capillary results in better
nebulization and helps to direct the spray towards the mass spectrometer. The resulting charged
spray of droplets from the capillary tip is distorted into a Taylor cone which undergoes rapid
evaporation of the solvent. This results in the continuous buildup of charge density until the surface
tension of the droplets is balanced by coulombic repulsion. At this point, called the Rayleigh limit,
large droplets result in the production of highly charged smaller droplets. These droplets can
continue the cycle until all the solvent is evaporated, leaving multiply charged analytes. The
resulting analyte ions have low internal energies; therefore, the structure of the analyte generally
remains intact (with no fragmentation) provided appropriate instrumental conditions are used. The
mechanism of ESI is shown in Figure 1.2.

5

Figure 1.2 Schematic representation of ESI process
(taken from Banerjee, S.; Mazumdar, S., Electrospray ionization mass spectrometry: a technique to
access the information beyond the molecular weight of the analyte. International journal of
analytical chemistry 2012.)
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1.1.3 Turbomolecular pumps (TMP)
The first turbopump was developed and patented by Dr. Willi Becker at Pfeiffer Vacuum in 1957.
It can produce a vacuum ranging from 10-3 to 10-8 Torr. These pumps usually consist of multiple
stacks of rotors with blades and stators in between, which are the fixed discs having blades as
shown in Figure 1.3. The rotors and stators are mounted in series. The motor makes the rotor spin
around the axis.
As the gas molecules enter through the inlet, they get hit by the blades of the rotor. The mechanical
energy of the blades is transferred to the gas. Due to the acquired momentum, the gas molecules
enter the holes of the stator leading them into the next set of rotors and stators. The transfer of the
gas through the series of rotors and stators directs it towards the exhaust where it’s collected by
the backing pump.
The flow of a gas is viscous flow at atmospheric pressure. This means that the individual gas
molecules interact more significantly with each other than they do with the walls of the container.
The momentum imparted to gas molecules by the turbopump is less significant compared to the
energy acquired after collision between the gas molecules. Therefore, a turbopump cannot function
at atmospheric pressure. In order to make it work, a rotary pump is employed to reduce gases
before the turbopumps starts to function. These reduce the pressure to ~10-3 Torr. At this pressure,
the gas molecules do not interact significantly with each other. Thus, the turbopump can effectively
impart momentum to each molecule resulting in vacuum of ~10-8 Torr. These pumps operate at
speeds of up to 20,000 rpm.

7

Figure 1.3 Turbomolecular pump diagram
(taken from http://www.repairfaq.org/sam/vacuum/tmpnotes.htm)
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1.1.4 Rotary pumps
These pumps attain pressures up to 10-4 Torr. They work by taking a volume of gas at the
atmospheric pressure, compressing the gas resulting in an increase in pressure and finally expelling
the gas to the atmosphere. The intake region of the vacuum chamber is at the same pressure as that
of the system, usually atmospheric pressure. Therefore, as the rotor moves, the inlet traps a large
volume of gas at system pressure. The gas is then transferred to the next region where the
movement of the rotor results in a decrease in volume and an increase in pressure. When the gas
pressure exceeds that of the atmosphere, the outlet valve opens and the gas is expelled. They are
mainly used as backing pumps for high vacuum pumps like turbopumps or diffusion pumps.

1.1.5 Microchannel plate detectors (MCP)
A MCP consists of an array of tiny detector tubes aligned parallel to one another. These tubes are
miniature electron multiplier channels and are usually made of lead glass. Parallel electrical
contact between each channel is provided by deposition of a metallic coating on both sides of the
array which act as input and output electrodes. The ion beam from the mass analyzer striking the
channels results in the production of an electron beam. Thus, a cascade within the MCP results in
electron multiplication of 104 – 107 with ultrahigh temporal resolution. Spatial resolution is limited
by the channel dimensions and spacing.
A phosphorescent screen placed behind the array of the MCP results in the production of light
flashes. These flashes of light are directed to an optical array transducer via fiber optics. The
transducer then converts the optical signaling to electrical signaling for processing.
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1.2

Proteomics

1.2.1 Overview
Proteomics is the study of the expression, structure, function and interactions of proteins. It
involves measuring, identifying and quantifying proteins expressed in a biological cell, tissue or
other specimen.
It is quite evident in biomedical research that biological/physiological processes are determined
by a large set of proteins rather than a single protein. These days chromatography in conjunction
with mass spectrometry plays a significant role in the field of proteomics.
In general, the first step is to isolate the proteins from the rest of the biological matrix including
lipids, DNA and other non-protein material. Conventionally, for proteomics, two-dimensional gel
electrophoresis (2-DGE) in combination with mass spectrometry has been used most extensively.
2-DGE separates the proteins based on their iso-electric point and molecular mass 5. Although this
technique and its variants are extremely useful, they impose some drawbacks. One of them is the
limited number of proteins that can be observed on the 2D gels. The expected number of proteins
in the human proteome is much higher than the protein spots observed on the 2D gels. Also, the
dynamic range offered by the 2D gels is limited by the ability to mainly analyze high M.W.
proteins (>30 kDa). Lack of reproducibility is another disadvantage in addition to time consuming
procedures.
Currently, the above mentioned conventional techniques are being replaced by capillary liquid
chromatography combined with tandem mass spectrometry (LC-MS-MS). It offers speed,
sensitivity and can interrogate thousands of different proteins.
10

For a highly complex sample like serum, a single dimensional separation using reversed phase
chromatography might not be sufficient. As a solution, the mixture can be separated using multidimensional chromatography including several combinations of size exclusion, reversed phase and
ion exchange chromatography. For example, peptides can first be separated based on their charge
using an ion exchange column followed by separation based on their hydrophobicities using a
reversed-phase HPLC column. This technique is known as multidimensional protein-identification
technology (MudPIT) 6. Such approaches offer very high separation capacities and high throughput
analysis allowing for the analysis of complex mixtures.

1.2.2 Potential applications
1. Protein profiling
MS technologies have contributed significantly in the generation of comprehensive proteome maps
for a number of organisms. Example, proteomic maps of microorganisms such as yeast or the
bacterium Deinococcus radiodurans are almost near completion

6-7

. A P. falciparum proteomic

project involved analysis of both the mosquito and human stages of the parasite and 2400 identified
proteins were reported 8
2. Studying protein-protein interactions
For these kinds of studies, a protein itself can be coupled to a stationary phase and be used as an
affinity reagent to isolate its own binding partners. Many protein interactions are known to occur
under specific cellular environment conditions. Therefore, MS based studies are likely to identify
only a part of the interactions that actually occur.
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3. Post translational modifications (PTM’s)
Post translational modifications (PTM’s) are the processing events that change the properties of a
protein by proteolytic cleavage or by covalent addition of a modifying group to one or more amino
acids 9. Numerous protein activities are altered by PTM’s. Therefore, MS based techniques are
applied to studying PTM’s. Electron transfer dissociation (ETD) or electron capture dissociation
(ECD) are the tandem mass spectrometry techniques most commonly used for characterization of
PTM’s. These techniques work by mainly fragmenting the peptide backbone and leaving the
modifications intact. The combination of ECD with high resolution FTICR has been applied to the
analysis of modified intact proteins 10-11.
4. Biomarker discovery
The presence or absence of a particular protein in a specific disease may provide a potential
biomarker for that disease. The potential for using shotgun or a global proteomic approached for
biomarker discovery was proposed by a number of groups. A group at Bristol-Myers Squibb
analyzed urine samples between healthy controls and cases suffering from inflamed pilonidal
abcess 12. Their study resulted in the detection and identification of many more protein biomarkers
using LC-MS/MS based approaches as compared to 2D GE methods. Other advantages of LC/MS
over 2DGE are the high speed of the experiments and requirement of minute sample amounts.
1.3

Peptidomics

1.3.1 Significance
There are a number of reasons why enrichment of low molecular weight proteins or peptides from
biological samples is done for biomarker discovery. Peptides are known to play a role in signal
transduction pathways for a number of diseases including convulsive disorders, liver diseases,
12

metabolic disorders, etc. 13-15. Also, large proteins are difficult to handle by mass spectrometry and
might not all be soluble under the same conditions. Most importantly, if the ultimate goal is to
identify the parent protein from the sequence, the mass spectrometer is more efficient at predicting
sequence up to 20 residues rather than whole proteins.

1.3.2 Methods for enrichment of peptides
The concentration of total protein in the serum is 60-80 mg/mL with a dynamic range of at least
10 orders of magnitude. The high abundance, high molecular weight proteins including albumins,
immunoglobulins and transferrin account for >90% of serum proteins. The higher abundance of
these proteins results in the ionization suppression of virtually all low abundance, low M.W.
peptides (and small proteins as well) in mass spectrometers making their detection difficult or
impossible 16. Therefore, it’s important to deplete the high abundance and generally higher M.W.
proteins to enhance the signal from low M.W significant peptides.
A number of techniques for enrichment of low M.W. proteins have been used in the past. Dye
ligands and protein A/G columns were tested for their performance to effectively deplete the high
abundance proteins 17. Molecular weight cut off filters have also been used in the past to remove
high M.W proteins using ultracentrifugation. Albumin is known to act as a carrier for transporting
a number of low M.W. proteins which can serve as potential biomarkers for diseases 18. A major
disadvantage of the above mentioned methods is their inability to release the low M.W. peptides
and proteins from carrier proteins such as albumin resulting in their removal as well.
We used organic solvent (acetonitrile) to precipitate and remove high M.W., abundant proteins
from the serum. This method resulted in disruption of the interactions between the small peptides
13

and their carrier proteins resulting in large number of additional peaks in the mass spectra. This
provides an opportunity for their analysis to discover potential biomarkers19.

1.3.3 Mass spectrometry of peptides
The protein depleted specimens are usually passed through a micro capillary column which is
coupled online to a mass spectrometer. The peptides are separated on the column using reversed
phase chromatography. It involves the use of a gradient elution method involving increasing
organic solvent concentration to elute the peptides in the increasing order of their hydrophobicities.
The peptides are distinguished by their masses and the signal intensity is directly proportional to
the abundance.

1.3.4 Collision induced dissociation (CID)
A technique called tandem MS is used to obtain the primary structure (sequence) of peptides.
Collision-induced dissociation (CID) is a soft fragmentation technique. It involves the isolation of
the particular species of interest which is collided with inert gases such as nitrogen, argon etc.
resulting in the breaking of the peptide at the peptide bond, i.e. between two amino acids. The
species that is fragmented is called the precursor ion and the ions produced after the fragmentation
are called the product ions. In CID, after the collisions, part of the kinetic energy is converted into
internal energy of the ions which finally undergo fragmentation.
The peptide fragmentation pattern produced during CID can be explained by the mobile proton
model 20. According to this model, the fragmentation pathways are charge directed. It proposes
that the proton is required at the cleavage site for the fragmentation to occur. Therefore, internal
14

energy imparted to the peptide ion results in the migration of the proton from the more basic sites
(N terminal or basic amino acids) to the peptide backbone leading to cleavage of the peptide bonds.
If a peptide contains no basic amino acids, the only site for protonation is the N terminus which
results in singly charged ions. This proton can migrate across the peptide backbone directing the
fragmentation reactions at the peptide bonds.
In contrast the presence of a basic amino acid residue in a peptide leads to production of doubly
charged species. One proton is attached to the basic amino acid and the other to the N terminus. In
this case, the proton attached to the basic amino acid is fixed, while the proton at the N terminus
is the mobile proton which can migrate through the peptide backbone as shown in Figure 1.4.

1.3.5 Peptide sequencing
The most informative fragmentation pattern is obtained by cleavage of the peptide bond
between the two amino acid residues. If the charge is retained on the N terminal, the resulting
ion is called a b ion and a y ion is produced when the charge is retained on the carboxy terminal.
For even more in-depth structural information, the product ions can be further fragmented, a
method called MSn. The fragment ions produced, depending on the cleavage site, are shown in
Figure 1.521.
The tandem MS spectra of peptides is searched using one of the search algorithms explained
below:
A) Using databases
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Figure 1.4 Mobile proton hypothesis for doubly charged peptides
(taken from Boyd, Robert, and Árpád Somogyi. "The mobile proton hypothesis in fragmentation of
protonated peptides: a perspective." Journal of the American Society for Mass Spectrometry 21.8
(2010): 1275-1278.)
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Figure 1.5 Chemical structure of a peptide with b and y fragments labelled (taken from Steen, H.;
Mann, M., The ABC's (and XYZ's) of peptide sequencing. Nature reviews Molecular cell biology
2004, 5 (9), 699-711).
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1) Programs that use a partial amino acid sequence to detect the parent proteins- BLAST, FASTA
These methods match the sequence of the query with the available database and give a probability
score based on the matching and non-matching amino acid in different regions. These methods are
also used to detect homologous protein sequences.
2) Programs that use peptide molecular weights for the search query- Peptide search, MS-Fit and
MOWSE
These are also referred to as mass mapping experiments. The proteins are digested with a specific
protease and the M.W. of peptides produced is measured accurately. These are then matched with
databases to find out which proteins if digested with same protease would produce one of several
of the same M.W. peptides.
3) Programs that use uninterpreted product ion spectra for the search query- SEQUEST,
MASCOT
These methods compare the experimental MS/MS spectrum with theoretical spectrum that has
been derived from every sequence in the database or from theoretically predicted fragments. A
score is given based on the extent of overlap. A best score is given for maximum overlap and
scores next to the score for the best matching peptide sequence are also given.
A) De novo peptide sequencing
When the computer algorithms are unsuccessful in interpreting a correct peptide sequence, another
approach called de novo sequencing can be undertaken. It involves the manual interpretation of
the peptide sequence based on the masses of the amino acid residues and m/z’s for the b and y
ions.
18

Ultimate confirmation of a peptide sequence requires the combination of de novo sequencing and
databases.

1.3.6 Quantitative proteomics

Different proteins have different ionization efficiencies depending upon their structures. Due to
this, quantification of proteins is difficult because one cannot infer the amount of a particular
protein present in a sample based on the abundance of the ionized species.
The most common way to quantify a protein is to add a known amount of a stable isotope synthetic
analogue that is identical otherwise to the compound to be measured but having a heavy isotope
containing amino acid substituted for typically one of the naturally occurring amino acids. Because
they have exactly the same ionization efficiencies, the concentration of the protein of interest can
be determined by adding or using a known amount of the synthetic analogue and referencing to it.
Although this method is useful, it is not possible to add a stable isotope for a number of different
proteins present in the sample. Therefore, some other approaches might prove to be more useful.
It’s mainly done by taking the aliquots of the same sample and isotopically labelling all the proteins
from one sample while not labelling the proteins from the other identical sample. Thus the relative
amounts of all the proteins can be measured by comparing the intensities of the labelled and the
unlabeled peaks for each of the proteins.
There are two methods commonly used for isotopically labelling the proteins. One involves
growing the cells in a medium which would incorporate and isotopically label all the proteins in a
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cell. Chemical derivatization of all the proteins in a sample using different isotope tags for each
sample is another method that is commonly used method.
A number of compounds have been reported for tagging the proteins in a complex mixture. One
method is called isotope coded affinity tag (ICAT) and involves a chemical reduction step followed
by alkylation to incorporate an isotope tag on cysteine residues in a protein 22-23. Another tagging
system modifies the lysine residues with O-methylisourea to form homoarginine 24.

1.4 Serum: an important specimen for biomarker studies

Useful biomarkers require or involve certain phases including discovery, confirmation and clinical
validation which requires the availability of a large number of organized patient samples. Blood
specimens including serum and plasma are one of the most easily accessible and commonly used
samples for biomarker discovery, while biopsy to obtain tissues is usually less well tolerated.
Serum samples are known to be preferred over plasma specimens 25. Due to the ease of collection,
serum samples are often collected and stored in biobanks allowing for research studies. The most
important aspect of discovering and validating a biomarker is the quality of specimens used. The
factors influencing the quality of the specimen include the conditions employed during collection,
minimizing time at each step, the care and precautions used in processing and how specimens are
stored. Therefore, blood should be collected without the use of a tourniquet, from the arm opposite
any IV lines, allowed to clot at room temperature for no less than 30 minutes and no more than 60
minutes, the clot should be immediately spun out at 4oC and the serum should be immediately
aliquoted to freezer-type tightly sealing tubes, immediately snap frozen and stored without thawing
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in a freezer until the time of analysis. It is recommended that for short term storage (1-2 weeks),
the samples should be stored at -200C, whereas for long term storage, -800C should be used.
It has been proposed that the proteome or peptidome of serum may indicate biological events. For
example, proteolytic events of the ex vivo coagulation may confirm cancer specific differences 26.

1.5

Lipidomics

1.5.1 Significance
Lipidomics is the comprehensive analysis of lipids in biological systems. Lipids are essential
cellular components that play important physiological roles: 1) they form membrane bilayers
providing spatial integrity and separating intracellular components from each other and the
extracellular environment. 2) They provide a hydrophobic environment facilitating interactions
between lipids and membrane associated proteins. 3) They act as a source of messengers for cell
signaling produced by action of intracellular enzymes. 4) They act as reservoirs for energy storage.
Global lipidomics using mass spectrometers was first described by Han and Gross in 2003. They
introduced the intrasource separation of lipid species depending upon their ionization efficiencies
directly from biological samples using ESI 27. The approach was termed “Shotgun lipidomics”.
Currently, lipidomics is mainly focused on the following areas: structural characterization of
known and unknown lipids from diverse classes, development of methods for the quantitation of
lipids at amounts as low as attomole to femtomole quantities and studying lipidomic alterations in
diseased states leading to biomarker discovery, aiding in disease diagnosis and progression and
also providing insights into the mechanism of diseases.
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Studying alterations in the cellular lipidome and quantifying the altered lipids has helped provide
new insights into the mechanism of some diseases

28-29

. Specific and important roles for lipids

from diverse classes in cellular signaling have also been reported. For example,
plasmenylethanolamine (PlsEtn), a subclass of phosphatidylethanolamine (a glycerophospholipid)
acts as a reservoir of arachidonic acid, facilitating membrane fusion, preventing its oxidation 30.
Specific triacyglycerols (TAG’s) in excess can trigger atherosclerosis and myocardial
dysfunction31.

1.5.2 Classification of lipids
A) Non-Polar lipids
These mainly include cholesterol, cholesterol esters and TAG’s. The dominating hydrophobic
region makes them highly hydrophobic. The basic structures are shown in Figure 1.6 32.
B) Polar lipids
1. Phospholipids- These are the most abundant class of polar lipids. They have at least one
phosphate group present at the sn-3 position of the glycerol backbone. The subclass of
phospholipids vary depending on the head group, namely phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylglycerol (PtdGro), phosphatidylinositols (PI),
phosphatidylserines (PS) and diphosphatidylglycerols (cardiolipins). Their structures are
shown in Figure 1.7 32. The most abundant phospholipids are PC and PE accounting for 75%
of total phospholipid mass in eukaryotic cell membranes. The complexity of phospholipids is
not just limited to the number of different polar head groups but also depends on the carbon
chain length of the fatty acyl components and their number of double bonds.
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Figure 1.6 general structures for cholesterol (A), cholesterol ester (B) and triacylglycerol (TAG)
(C). R, R1, R2 and R3 represent aliphatic chains
(taken from Han, X.; Gross, R. W., Shotgun lipidomics: electrospray ionization mass spectrometric
analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples.
Mass spectrometry reviews 2005, 24 (3), 367-412).
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Figure 1.7 General structures for different classes of phospholipids
(taken from Han, X.; Gross, R. W., Shotgun lipidomics: electrospray ionization mass spectrometric
analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples.
Mass spectrometry reviews 2005, 24 (3), 367-412).
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2. Sphingolipids-These contain a sphingosine backbone or an analog and represent approximately
5-10% of total lipids present in most brain cells and 30% of total lipids in human white matter
33

. Depending on the polar head group attached to the ceramide, sphingolipids can be classified

into sphingomyelin (SM), cerebrosides, sulfatides, glucosylceramides, lactosylceramides and
other glycosphingolipids having multiple sugar rings as shown in Figure 1.8 32.

3. Glycolipids-This class includes primarily glycosphingolipids and glycoglycerolipids. The
hydrophobic core of the glycosphingolipids is a ceramide backbone, while that of
glycoglycerolipids is a diacylglycerol (DAG) backbone.

C) Metabolites
The lipid metabolites are produced from the parent lipid species by enzymatic action. These
include acylcarnitines, nonesterified fatty acids (NEFA), fatty acid esters, lysolipids, eicosanoids
etc. A lot of lipid metabolites are known to act as second messengers biologically.

1.5.3 Classification of lipids based on their electrical dispositions
The first category is of the anionic lipids which carry one or more negative charges at physiological
pH. This group includes PI, PS, PtdGro, cardiolipins, acylcoA, sulfatides, and would carry a
negative charge only if exposed to alkaline pH.
Consequently, their ionization efficiencies are lower than those of the anionic lipids. The lipids in
this category are PE, lysoPE, ceramides etc. The third category of lipids is the electrically neutral
lipids at alkaline or physiological pH. The lipid classes include PC, lysoPC, DAG, TAG, etc.
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Figure 1.8 General structure and classes of sphingolipids
(taken from Han, X.; Gross, R. W., Shotgun lipidomics: electrospray ionization mass spectrometric
analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass
spectrometry reviews 2005, 24 (3), 367-412).
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1.5.4 Separation of lipids in the positive or negative ion mode through ESI
The ionization efficiency of a lipid depends on its tendency to lose or gain (oxidized or reduced)
charge in the electric field. The lipid species carrying an inherent charge ionize more readily than
the ones that do not carry an inherent charge. Ionization can also be achieved in the ESI source
through the formation of adduct ions using cations or anions. Under the presence of an electric
field, a dipole moment sufficient enough could be induced to make the lipid species interact with
either an adduct cation or anion to form lipid-adduct ions.
The ionization efficiencies depend upon the degree of the dipole potential induced in the molecular
species. For example, a PC contains a large dipole moment in the zwitterionic polar head group.
Therefore, it rapidly ionizes to form M+H+ or M+Na+ in the positive ion mode. In the negative ion
mode, a PC can form M+Cl- or M+OAc-. Because head group of a PC contributes in a major way
to the dipole moment, the ionization efficiencies of different PC species varying in carbon chain
length are nearly identical. On the other hand, TAG’s are nonpolar lipids forming ammoniated,
sodiated or lithiated adducts. A polar head group is absent and the dipole moment is influenced by
the carbon chain length. Therefore, the ionization efficiencies of different TAG species are
different depending on the number of carbon atoms and double bonds.
For a lipid extract obtained from a crude biological sample, all the anionic lipid species would be
observed in the negative ion mode. After addition of a base to make the extract slightly basic, all
the weakly anionic lipids would also be observed in the negative ion mode. All the neutral polar
lipid species would show up in the positive ion mode. Setup for intrasource separation of lipids
through ESI is shown in Figure 1.9 32.
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1.5.5

Tandem mass spectrometric based lipidomics

The four MS/MS modes used in lipidomics are:
1. Product ion analysis mode
In this mode, the precursor ion of interest is first selected by the first analyzer which acts as a filter
to transmit only the ion of interest. The ion of interest is then fragmented in the collision cell to
form a number of product ions which are analyzed by the second mass analyzer. The structure of
the precursor ion may then be elucidated from the fragment ions.
2. Precursor ion scanning mode
In this mode, the second mass analyzer focusses on the fragment ion of interest and scans different
m/z from the first mass analyzer. All the m/z’s which produce that particular fragment ion are
selected. It is useful to detect different species belonging to the same lipid class.
3. Neutral loss scanning mode
In the neutral loss scanning mode, both the first and second analyzers are scanned simultaneously
to find a particular offset mass between the two. For some lipid species, the product ion produced
by the fragmentation of the precursor ion corresponds to a neutral loss of a particular mass and
likely a particular structural component. All the lipid species belonging to a class producing a
particular neutral loss fragment can be identified using this technique.
4. Selected reaction monitoring mode (SRM)
In this mode, the transitions between the precursor and the product ions are previously known.
Both the first and second analyzers are focused on selected ions with m/z=M and m/z=p, where p
represents the product ion of parent or precursor ion M.
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Figure 1.9 Intrasource separation of lipid species through ESI directly from the crude extract.
(taken from Han, X.; Gross, R. W., Shotgun lipidomics: electrospray ionization mass spectrometric
analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples.
Mass spectrometry reviews 2005, 24 (3), 367-412).
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When either one or both the analyzers are set to record multiple ions, it’s called multiple reaction
monitoring (MRM). For SRM/MRM mode, the mass spectrometer is coupled with HPLC. These
techniques provide high sensitivity and specificity because of the high duty cycle of transitions of
interest and are commonly used for the quantitative analysis of a lipid species of interest.
These different modes are shown in Figure 1.10 34.

1.5.6 Mass spectrometric analyses of the lipid species
1. Analysis of anionic lipid molecular species
Those species possessing a negative charge inherently can be analyzed in the negative ion mode
at neutral pH. For example, abundant deprotonated peaks for anionic lipids including PI, PtdGro,
PS and cardiolipins were observed in the ESI mass spectrum of a crude lipid extract from mouse
myocardium, whereas it displayed low abundance pseudo-molecular ions for otherlipid classes
like PC and PE 32. In the negative ion mode, the molecular ion species of PI yielded a fragment
ion at m/z 241. Therefore, all the species corresponding to PI can be identified by precursor ion
scanning or product ion analysis. Similarly, lipids from the PS class can be identified by neutral
loss scanning of 87 amu. Also, a product ion at m/z 153 corresponding glycerophosphate are
produced from deprotonated anionic phospholipid species including PtdGro, cardiolipins etc.
2. Analysis of weakly anionic lipid molecular species
Addition of a weak base in low concentrations will result in deprotonation of weakly anionic lipid
species including PE, lysoPE and eicosanoids, therefore displaying abundant deprotonated peaks.

30

Figure 1.10 Tandem mass spectrometry modes for analyses of lipid species
(taken from Multi‐dimensional mass spectrometry‐based shotgun lipidomics and novel strategies
for lipidomic analyses. Mass spectrometry reviews)
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The combinations of acyl chains present in PE can be identified by looking for the individual
fragment ions. For example, m/z 255.2 is for 16:0, m/z 279.2 is for 18:2, m/z 281.2 for 18:1 and
m/z 303.3 for 20:4. Although the anionic lipids ionize much more readily as compared to weakly
anionic lipids, the ion suppression of PE species is not affected by anionic species. This is mainly
because of the low abundance of anionic lipids relative to PE molecular species resulting in
minimum interference during the ionization process.
3. Analysis of electrically neutral lipid species
These species are mainly detected in the positive ion mode. The highly polar lipid species including
PC, lysoPC and SM are easily ionized with protons, whereas relatively less polar lipids e.g. TAG
require ammonium, sodium or lithium ions to form adducts. The fragmentation spectrum of
choline containing lipid species like PC, lysoPC and SM display product ions with m/z 59, 104
and 184 corresponding to trimethylamine and choline and phosphocholine moieties. The parent
SM species can be distinguished from PC species by the nitrogen rule. The nitrogen rule states that
organic compounds containing exclusively H, C, N, O, Si, P, S and the halogens either have odd
nominal mass that indicates an odd number of nitrogen atoms or even an even nominal mass that
indicates an even number of nitrogen.
The combinations of acyl chains can also be determined by analyzing the neutral loss of fatty acids
from the parent in the product ion spectrum.
TAG’s contain three fatty acid chains attached to the glycerol backbone. Although non-polar,
abundant peaks are observed for TAG adducts (sodium, lithium or ammonium) in MS1 spectrum.
Because of the absence of a head group, the ionization efficiencies for TAG’s mainly depend on
the acyl chain length and the number of double bonds.
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1.5.7 Approaches for lipidomic analysis

The first approach used for lipidomics is an LC-MS based approach where separation of lipids
takes place on a column prior to ESI-MS. The other major approach involves direct infusion of a
lipid extract into the mass spectrometer through ESI. This approach is termed as shotgun
lipidomics.
A) LC/MS based approaches:
The combination of ESI-MS with LC separation provides high sensitivity and resolution. Column
separation also facilitates the analysis of isobaric compounds with different hydrophobicities. The
LC-MS based approaches includes SIE (selective ion extraction), SRM/MRM and data-dependent
analysis. In SIE, selected ions are extracted from the chromatogram after the LC run. The ion peak
area of all the species of interest can be compared either to a standard curve of the same molecular
species or ion peak area of an internal standard under identical experimental conditions. This
approach is useful for quantitation of targeted low abundant species whose standard curve could
be generated. However, this approach cannot be used for large scale quantification of lipids. The
interference caused by coexisting lipid species in the same peak having similar hydrophobicities
is a drawback of this approach. In contrast to SIE, SRM/MRM is preferable because the
quantification is dependent on the fragment ion intensities specific to the parent ion of interest.
A large number of studies have been carried out in the past to quantify lipid species using LC/MS.
For example, quantification of ceramides from human stratum corneum has been successfully
performed using normal phase LC/MS 35. In a study LC/MS/MS facilitated the quantification of >
50 fatty acyl amino acids (35) 36.
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B) Shotgun lipidomics
Direct infusion of a lipid extract into ESI-MS was first described by Han and Gross in 1994. This
approach is widely termed as shotgun lipidomics. It facilitates high throughput analysis of a
lipidome directly from the lipid extract of complex biological samples. An advantage of the direct
infusions over LC/MS is this high throughput sample analysis requires less time. The methods
most commonly used for shotgun lipidomics are:
1. Tandem MS based shotgun lipidomics
As described earlier, most of the lipid species belonging to a particular class produce a
characteristic fragment ion associated with the head group specific to that class. Therefore, all the
lipid species belonging to a particular class can be isolated, measured and identified using
precursor ion scan or neutral loss scan. This offers the advantages of simplicity, efficiency, high
sensitivity, ease of management and faster analysis. The filtering process of MS/MS results in a
high S/N ratio.
There are several limitations associated with this approach. Firstly, the aliphatic constituents
associated with different lipid species belonging to the same class are not identified. Secondly, the
detection with MS/MS approach might not always be specific to the particular class. For example,
the fragment ion at m/z 184 can be produced by species belonging to PC or SM; therefore, it can
easily produce assignment artifacts. Lastly, accurate quantification of the lipid species might not
be simple because of slightly different fragmentation pathways of the species belonging to the
same lipid class.
Despite the described disadvantages, many laboratories have adopted this approach for lipid
analysis. For example, it’s widely used for plant lipidomics, detecting changes in lipids in response
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to individual conditions or stresses
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. The identification of PC subclasses and the individual

molecular species belonging to PC have also been achieved using NLS and PIS from their lithiated
molecular ions 39.
2. High mass accuracy lipidomics
Currently, the Q-TOF mass spectrometer offers an increased duty cycle improving the detection
sensitivity. TOF analyzers can detect ions simultaneously, providing high mass accuracy and
resolution resulting in exact mass determination of the precursor or fragment ions minimizing false
positives.

1.5.8

Application of lipidomics in disease biomarker discovery

Lipids are known to play important physiological functions including acting as a source of energy,
maintaining cell membrane integrity and being involved in cell signaling pathways. Therefore, it’s
important to consider and detect lipids involved in disease processes which may reflect disease
states and indicate about the mechanism of the disease.
A number of studies have proven that dyslipidemia or abnormal lipid metabolism can lead to a
number of human diseases including diabetes 40, obesity 41, atherosclerosis 42 and brain disorders
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. Therefore, studying alterations of individual molecular species of lipids in diseased specimens

can help in detection of potential lipid biomarkers indicative of that disease.
The most common workflow for detecting lipid biomarkers includes the following steps. Lipid
extraction from biological samples including serum, tissue or other body fluids is carried out for a
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set of cases and controls. The crude lipid extract is either first separated using LC or GC and then
passed through ESI to MS or directly infused into the MS through ESI. Following that, a peak list
of individual molecular species of lipids belonging to diverse classes from the mass spectrum is
generated. Next, the data is normalized and subjected to various statistical tests to detect peaks
which are statistically different between the cases and controls. Finally, the detected lipid
biomarkers are correlated with metabolic pathways and their possible role in the mechanism of the
disease is interpreted.
A number of lipidomic studies have been helpful in detecting novel lipid species that could serve
as potential biomarkers for a number of diseases. For example, in a study, phospholipid profiling
in plasma samples of diabetic mellitus-2 (DM-2) cases and controls was done using an LC-MS/MS
approach to detect potential lipid markers. This study led to discovery of four lipid markers
including two PE and two lyso-PC molecular species that discriminated DM-2 cases from controls
44

. In another study, lipid profiling of liver tissues obtained from wild type and APOE*3-Leiden

transgenic mice suffering from diet induced hyperlipidemia and atherosclerosis was done using
LC-MS on both cases and controls 45. The results found higher levels of two lysoPC species in the
APOE*3-Leiden transgenic mice. Also, a number of TAG species were found to be higher in these
transgenic mice. Ceramides have been found to be increased in neuropathic diseases
number of TAG’s were found to be elevated in cardiovascular diseases 46.

1.6

Preeclampsia
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and a

1.6.1

Background

Preeclampsia (PE) is a serious life threatening gestational disorder. It occurs in 5-8% of
pregnancies worldwide and is a leading cause of fetal and maternal deaths and morbidity 47. As
established by International Society for the Study of Hypertension in Pregnancy (ISSHP), PE is a
state of new onset hypertension after 20 weeks of gestational age together with proteinuria,
followed by the postpartum normalization of the symptoms within 3 months. The thresholds
defined for hypertension in PE are a systolic blood pressure of >140 mm Hg and a diastolic blood
pressure of >90 mm Hg measured twice within an interval of at least 4 h, whereas proteinuria is
defined to be the presence of >300 mg/day of urinary protein

48

. Furthermore, the ISSHP has

defined PE to be severe if the blood pressure is >160 mm Hg systolic and >110 mm Hg diastolic
and proteinuria of >5 g/day 49. Despite the fact that proteinuria has been conventionally considered
a requisite for diagnosis of PE, its role as a marker is debatable
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. Also, the appearance of

additional complications in PE can occur and is termed HELLP (hemolysis, elevated liver
enzymes and low platelet counts) syndrome characterized by thrombocytopenia, microangiopathic
hemolytic anemia and hepatic dysfunction 51. In some cases severe PE can progress to eclampsia
which involves the development of seizures antepartum, intrapartum or postpartum, probably due
to cerebral vasoconstriction or vasospasm, ischaemia, cerebral edema and/or cerebral
haemorrhage. Other maternal symptoms considered for clinical diagnosis of PE include renal
insufficiency (creatinine >0.09 mmol/L), liver disease, neurological problems (hyperreflexia with
severe headaches, visual disturbances), hematological disturbances and fetal growth restriction 49.
Fetal complications include prematurity and low birth weight. Collectively, taken together, a wide
range of symptoms makes PE a syndrome rather than a disease.

37

Despite years of research, the etiology of the disease is not known. Indeed, PE has been known
since the times of ancient Egypt around 3000 years ago, where it was first reported as a pregnancy
related disorder 52. However, it has been accepted that the presence of the placenta is responsible
and/or necessary for the disease which is supported by the fact that the symptoms are relieved
following its removal
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. It is defined as the “disease of theories” as exhibited by its having no

decided cause 54.

1.6.2 Pathogenesis of PE
The first step that is proposed to initiate the PE process is the inadequate remodeling of the uterine
spiral arteries leading to improper perfusion of the fetal-placental unit. This further results in the
placenta becoming hypoxic. The alternate periods of hypoxia and re-oxygenation within the
placenta triggers oxidative stress and increases placental apoptosis and necrosis 55. This shedding
of placental debris into the maternal circulation leads to systemic endothelial dysfunction and an
adverse inflammatory response 51.

1.6.3 Biomarkers for PE
Despite a number of clinical studies, there is no single reliable parameter for early diagnosis of
PE. Currently, a number of biomarkers have been proposed for PE. The most commonly studied
are 1. Angiogenic factors- vascular endothelial growth factor (VEGF) and placental growth factor
(PlGF). 2. Anti-angiogenic factors- soluble fms like tyrokinase (sflt1) and soluble endoglin.
Other proposed candidate markers for PE are Placental Protein 13, P-Selectin and PregnancyAssociated Plasma Protein A (PAPP-A).
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Although a number of evaluations have been performed on these markers, their use is limited due
to lack of sensitivity and specificity and inability to diagnose PE at an early stage 56.
Therefore, there is a need for detection of set of novel biomarkers which can differentiate patients
at risk for PE from controls at a very early stage. We carried out a study using our serum proteomic
approach to detect low M.W. biomarkers for PE as elaborated in Chapter 2.
We also used a lipidomic approach to detect and identify potential lipid biomarkers for PE
specifically (details in Chapter 3).

1.7

1.7.1

Alzheimer’s disease (AD)

Background

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder and is the most common form
of age related dementia in modern society 57. It is characterized by progressive loss of cognitive
functions. The early signs mainly include memory loss and mild behavioral changes with gradual
progression to dementia. It is estimated that approximately 25 million people worldwide currently
have AD, and the number of affected people is estimated to be increased to 80 million by
204058.The risk factors mainly linked to the incidence of AD include age, gender (females are
more likely to be affected), genetic factors, head injury and Down’s syndrome.
Mild cognitive impairment (MCI) is proposed to be an early phase of cognitive decline that
precedes dementia. MCI patients may progress to AD, vascular disease and other kinds of
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dementia. A study showed that people with MCI were 6.7 times more likely to develop AD than
cognitively normal individuals 59.

1.7.2

Clinical Dementia Rating Scale (CDR) for AD

The 5 stages of dementia used to evaluate the progression of symptoms in patients with dementia
are
1. CDR 0 or no impairment: This stage represents no memory problems, proper orientation in time
and space, normal judgement and the ability to take care of the all of the personal needs.
2. CDR 0.5 or very mild dementia: It represents minor memory inconsistencies but the ability to
manage personal needs is not affected.
3. CDR 1 or mild dementia: Symptoms include moderate memory loss, geographic disorientation
and difficulty in handling problems. Social judgement is usually maintained.
4. CDR 2 or moderate dementia: It includes severe memory loss, severe difficulty with time and
space orientation, social function usually impaired and there is no pretense of independent function
outside home.
5. CDR 3 or severe dementia: It is accompanied by severe memory loss, complete judgment
impairment, can’t solve problems and inability to take care of personal needs.
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1.7.3

Pathophysiology of AD

Currently, AD is believed to be driven by two biochemical processes. The first involves the
extracellular deposition of beta amyloid (Aβ) which is a 36-43 amino acid peptide cleaved from
the parent protein amyloid precursor protein (APP) by action of enzymes β and γ secretase. Further,
the Aβ monomer polymerizes to soluble oligomers and then to insoluble fragments such as Aβ 42
which finally precipitates to amyloid fibrils resulting in deposition.
The second biochemical process associated with AD is the formation of neurofibrillary tangles due
to abnormal processing and accumulation of tau protein. Tau protein forms aggregates by twisting
filaments around each other. These aggregates then interfere with normal cellular processes by
displacing organelles and impairing axonal transport.

1.7.4 Current Neuroimaging techniques
Disease pathogenesis may affect the brains of patients well before the actual clinical symptoms of
AD occur. Therefore, early diagnosis may help in the prevention of disease progression and also
benefit development of effective treatment.
Neuroimaging techniques used for diagnosing AD are described below.
1) Structural neuroimaging
Magnetic resonance imaging (MRI) allows measurement of hippocampal volume, which is a
known established AD marker

60

. Multiple studies have confirmed hippocampal neuron loss at

post-mortem in AD patients61-62.
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2) Functional neuroimaging
Decrease in regional blood flow and glucose metabolism preceding cerebral atrophy is known to
occur in AD patients

63

. Functional imaging with fluorodeoxyglucose positron emission

tomography (FDG-PET) shows characteristic glucose hypometabolism in temporoparietal areas
of AD brain due to synaptic loss 64. Multiple studies have distinguished established AD from other
healthy controls with 90% sensitivity and specificity using FDG-PET 65.
PET can also detect binding of labelled molecules to Aβ indicating Aβ plaques in AD brains

66

.

Although these imaging techniques can improve diagnosis, their use is limited to small scale
studies. This is because of expensive instrumentation, their invasive nature and laborious
methodologies.

1.7.5

Current proposed biomarkers for AD

A number of candidate markers proposed for AD in CSF, serum, plasma and urine are shown in
Table 1.1 67.
Despite a number of proposed candidate biomarkers for AD, the definite diagnosis can only be
made by post mortem histopathological examination of brain tissue having amyloid plaques
containing a core of Aβ peptide and neurofibrillary tangles of tau protein.
Therefore, there is a need for detection of panels of novel biomarkers that could aid in the early
diagnosis of AD and help in the development of treatment therapies.
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1.7.6

Lipid biomarkers for AD

Lipids could be directly involved in the biochemical pathway of AD or could be produced as a
result of the disease. A number of studies have shown alteration of lipids in AD mentioned in
Chapter 4. Therefore, lipids could prove useful as potential markers for diagnosing AD at an early
stage. We carried out a study to characterize the alterations in lipid species from different classes
between AD cases and controls using direct infusion ESI mass spectrometry.
The methods and results are elaborated in detail in Chapter 4.
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Table 1.1 Select candidate fluid and imaging biomarkers of AD
(taken from Cell-based compositions and methods for treating conditions of the nervous system.
Google Patents: 2008)
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Chapter 2

Serum Biomarkers Predictive of Preeclampsia

Disclaimer: This chapter is mainly reproduced from published research article: Anand, S., Bench
Alvarez, T. M., Johnson, W. E., Esplin, M. S., Merrell, K., Porter, T. F., & Graves, S. W. (2015).
Serum biomarkers predictive of pre-eclampsia, Biomarkers in medicine, 9(6), 563-575.

2.1

Abstract

Materials and methods: Sera obtained at 12-14 weeks of pregnancy from 24 cases who later
developed PE and 24 controls with uncomplicated pregnancies were processed and analyzed using
a serum proteomic approach.
Results: Many statistically significant serum PE biomarker candidates (>60) were found
comparing cases and controls. In addition, logistic regression analysis modeled biomarker data
resulted in 14 different multi-marker combinations having high detection sensitivity and specificity
(AUC>0.9).
Conclusion: Developed panels of serum biomarkers appeared effective in identifying pregnant
women at 12-14 weeks gestation at risk of PE later in their pregnancy.

2.2

Introduction

Preeclampsia (PE) is a potentially life-threatening pregnancy disorder. It occurs in 5-8% of
pregnancies worldwide and is a primary cause of fetal and maternal morbidity and death 1. PE has
been defined by new onset hypertension and proteinuria, but can worsen to involve several
systems.
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Although there has been extensive research, the early etiology of PE is incompletely understood.
It is widely accepted that the placenta is required for the disease which is supported by the
observation that symptoms reverse rapidly following its removal2,3. PE historically has been called
the “disease of theories” based its many proposed causes4.

Despite no definitive cause, and potentially no single cause, there is evidence for a number of
potentially contributory problems in PE that occur prior to clinical presentation of the disease. For
example PE is associated with an incomplete invasion and remodeling of the maternal uterine
spiral arterioles by extravillous trophoblasts leading, it is thought, to ischemia and hypoperfusion
of the placenta 5.

Further, it has been proposed that alternating recurrence of hypoxia-

reoxygenation in the uteroplacental region leads generation of reactive oxygen species (ROS) 6.
There also appears to be altered expression of angiogenic and anti-angiogenic factors in the
maternal circulation prior to established PE 7. Such early changes hold out the possibility of
biochemical changes that may foreshadow the disease and could be used as biomarkers.

While knowing that a pregnant woman is at risk of PE, presently, treatment or prevention
of PE remains limited. Several clinical trials have investigated the use of various agents to prevent
or reduce the incidence of PE, including low dose aspirin (as an anti-inflammatory and anticoagulant); vitamins C and E (as antioxidants and agents countering ROS) and calcium
supplementation (as a potential mediator of hypertension) but these did not provide a general
reduction of PE incidence overall although there is evidence of each providing a benefit to a small
subset of pregnant women

8-10

. Again, the potential heterogeneity of PE may obscure selected

benefits. Drug interventions are limited to blood pressure control in symptomatic PE women and
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steroids to hasten fetal lung maturation when premature delivery may be required. Other drug
therapies have yet to be established and approved. Nevertheless, having a reliable set of predictive
biomarkers might allow for more appropriate levels of clinical surveillance for both at-risk and
not-at-risk pregnant women.

Biomarkers have been proposed for PE. They have been chosen most often because of
their being altered in clinically established, active disease. The most highly studied of these are
markers of angiogenic imbalance, with elevated serum levels of the anti-angiogenic factors,
soluble fms-like tyrosine kinase-1, sFlt-1, and soluble endoglin, sEng, and decreased levels of proangiogenic factors, i.e. placental growth factor, PlGF and vascular endothelial growth factor,
VEGF

7, 11-12

. However, as predictive markers, they have shown limited accuracy in unselected

populations13-16. Furthermore, they are not entirely specific to PE with comparable changes found
in other pregnancy-related complications, e.g. intrauterine growth restriction without PE

17

.

Additionally, it has been shown that prophylactic use of anti-oxidant vitamins, while failing to
reduce the incidence of PE, did surprisingly normalize these pro-angiogenic/anti-angiogenic
factors in those women who later had PE, suggesting that environmental factors, such as nutrition,
can directly affect them without changing risk for disease.

Other less studied, potentially

predictive PE biomarkers are placental protein 13 (PP13), P-selectin and pregnancy associated
plasma protein A, but they also demonstrate low predictive value. Consequently, there is on-going
need for a better set of PE biomarkers.

Proteomics is an analytical approach that couples chromatographic separations with mass
spectrometry.

These methods can survey hundreds to thousands of different molecules
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simultaneously, creating the possibility of a more global, unbiased assessment of potential
diagnostic or predictive biochemical changes accompanying or predating clinical disease.
The use of serum as part of proteomic approaches to finding biomarkers is challenging.
Not only is the target specimen complex, a more significant problem is the presence of ~30 highly
abundant proteins. High abundance species cause ion suppression in MS-based methods obscuring
thousands of lower abundance species. Hence, there is always a tradeoff: focus on large proteins
and suffer ion suppression losing thousands of potentially informative biomolecules or focus on
lower molecular weight species and eliminate potentially informative proteins. Previously, there
have been few, if any, attempts at global serum proteomic approaches to identify serum or plasma
PE biomarkers, certainly none that have fully eliminated high abundance proteins and none that
have interrogated lower molecular weight, low abundance species. Our approach is new and
focuses on the less abundance (nM or lower), lower molecular weight (<10,000 daltons) proteins,
peptides and lipids predicting PE. In doing so, the approach increases dramatically the number of
biomarkers interrogated by MS (>5000 additional novel analytes), increasing the possibility of
finding important predictive PE biomarkers. This approach at a minimum complements previous
studies. In this study, this approach has been applied to serum from pregnant women collected at
12-14 wks pregnancy and markers have been sought to allow for prediction of later PE. These
results are described here.

2.3 Methods
2.3.1 Patient Population
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Serum specimens utilized for this PE study were obtained from the Department of Obstetrics and
Gynecology, University of Utah School of Medicine and from Intermountian Healthcare and
represent sera previously collected from pregnant women at 12-14 weeks gestation as part of a
prospective study that considered universal potential complications. There were 24 controls,
having term uncomplicated pregnancies and 24 cases, which developed PE later in the same
pregnancy. The diagnosis of PE followed guidelines established by the American Congress of
Obstetricians and Gynecologists and the International Society for the Study of Hypertension in
Pregnancy 1. Women on medications or with major intercurrent disease were excluded, including
those with diabetes, renal disease, or preexisting hypertension. Demographic information on the
women whose speciments were included in the study in summarized in Table 2.1. All women
were Caucasian subjects reflecting the racial make-up of the general hospital population. The
study was approved by representative Institutional Review Boards at both the University of Utah
and Brigham Young University. We note that at the outset of this research we had anticipated
completing a follow-up, confirmation study, but found that there were no additional specimens
available from cases that had not been thawed and refrozen, perhaps repeatedly. We were unaware
of other studies that collected specimens prospectively at 12-14 gestation, processed expeditiously
and kept frozen until analysis available to us.

2.3.2 Sample Preparation
As part of the original protocol, blood was collected, allowed to clot (~60 min) and the serum was
separated immediately from the clot by centrifugation and stored at -800C until processed further.
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Table 2.1 Demographic Data for Study Groups
Maternal Age Gestational
(yr)
Age (wks)

Body mass Birth weight Max. SBP Max. DBP
index
(gm)
mm Hg
mm Hg
(BMI)

Cases

28 ± 1.2

35 ± 0.8

25.5 ± 1.2

2467 ± 200

159 ± 3.4

103 ± 1.6

Controls

28 ± 0.97

38 ± 0.35

21.2 ± 1.4

3447 ± 108

132 ± 2.8

83 ± 2.3

SBP: Systolic blood pressure, DBP: Diastolic blood pressure
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In order to selectively focus on low MW peptides, a protocol was followed to deplete proteins
from the sera by adding acetonitrile in a ratio to serum of 2:1 18. This removed high abundance,
high MW proteins. The apparent protein concentration of protein-depleted samples was
determined using a Bio-Rad microtiter plate protein assay following the manufacturer’s method
(Bio-Rad Laboratories, Hercules, CA). An aliquot containing 4 µg apparent protein was
transferred into a fresh microcentrifuge tube. The aliquot was lyophilized (CentriVap Concentrator
Labconco Corporation, Kansas, City, MO) to less than 20 µL, and the volume was brought up to
20 µL with HPLC grade water and acidified with 20 µL of 88% formic acid. The specimens were
loaded onto a capillary liquid chromatography-tandem mass spectrometer system (cLC-MS) via
autosampler injection (Dionex Corporation, Sunnyvale, CA).

2.3.3 cLC-MS Analysis of Protein Depleted Specimens
Specimens were introduced onto an LC system utilizing a 1 mm (16.2 μL) microbore guard
column (Upchurch Scientific, Oak Harbor, WA) coupled to a 15 cm x 250 μm i.d. in-house packed
capillary column (POROS R1 reversed-phase media, Applied Biosystems, Framingham, MA). The
instrument employed an LC Packings Ultimate Capillary HPLC pump system, with a FAMOS®
autosampler (Dionex Corporation, Sunnyvale, CA) controlled by Analyst QS ® software (Applied
Biosystems, Foster City, CA). The chromatographic separation gradient used an aqueous phase
(98% HPLC grade H2O, 2% acetonitrile, 0.1% formic acid) and an organic phase (2% H2O, 98%
acetonitrile, 0.1% formic acid). Details of the elution gradient used and other parameters of the
method have been described previously 18.
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During the chromatographic separation, eluate from the fractionated samples was
introduced into a QSTAR Pulsar I quadrupole orthogonal time-of-flight mass spectrometer through
an ESI (electrospray ionization) source. The MS data for each sample was collected for m/z 500
to 2500 from 5 to 55 min of the cLC elution with mass spectra obtained every 1 sec. The elution
profile of each cLC fractionated sample was reported as the total ion chromatogram (TIC) and the
results analyzed using Analyst QS® 1.1 software (Applied Biosystems, Foster City, CA).
Following the void volume (~12-15 min), ~25 min of the remaining 55 min gradient was divided
into ten ~2 minute regions or windows based on previously described serum time markers

19

.

Within each two-minute window, the spectra for cases and controls were overlaid and color-coded
to distinguish the two comparison groups for analysis. Visual inspection was conducted and peaks
with apparent quantitative differences between cases and controls were recorded for further
analysis. The intensities of these potential markers were recorded for each of the specimens in the
initial specimen set using the extracted ion chromatogram (XIC) function and were used for
statistical analyses. Additionally, a co-eluting species having comparable intensity for the cases
and controls were chosen as the reference peaks. Their intensities were determined and used for
the normalization of the potential biomarkers.

2.3.4 Statistical Analyses
The peak heights of potential markers of interest from the initial sample set were subjected
to Student's T-test to determine statistical significance of case versus control differences observed
in the visual inspection step. A p-value of <0.05 was considered statistically significant, although
markers with a p-value of less than 0.1 were also included for modeling biomarker panels with
higher specificity and sensitivity. Thus, all the potential markers with a p-value of less than 0.1
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(66 markers) were subjected to biomarker panel development using a forward selection, leave one
out, logistic regression approach

20-21

. It is recognized that a simple T-test is not a sufficient

statistical test. However, the field of proteomics is emerging and there is no agreed upon statistical
approach. Typically, multi-marker modeling and/or retesting of markers increase confidence in
their usefulness. The forward selection process was done in conjunction with logistic regression
analysis and receiver operator characteristic (ROC) curves were generated to allow for sensitivities
and specificities to be considered. The ROC would ideally be used with larger numbers but
provide a sense of the usefulness of biomarker combinations.

2.3.5 Tandem MS Identification of Significantly Different Candidate Biomarkers
Previously assayed samples having high abundance of a candidate PE biomarker were
selected for fragmentation studies. A quantity of 5-20 µg of the sample was treated with 2.5 µL
of 88% formic acid and loaded onto cLC-MS-MS system. Prior to fragmentation experiments, the
specimen was submitted to two cLC-MS runs to determine the exact elution time of the molecule
of interest. If a consistent elution time was obtained, a two minute window comprising one minute
before and one minute after the candidate peak height maximum was directed into the
fragmentation cell and fragmentation data collected. The same guard column, capillary column
and column packing were used as described above. The aqueous phase was 98% HPLC grade H2O,
2% acetonitrile, 0.1% formic acid and the organic phase was 2% H2O, 98% acetonitrile, 0.1%
formic acid. The initial cLC-MS runs lasted for 40 min starting with 3 min of 95% aqueous phase
and 5% organic phase, followed by a linear increase to 60% organic phase over 20 min. Following
that, the gradient was then further increased to 95% organic phase over 5 min and held at 95%
organic for 6 min. Finally, the gradient was then returned to 95% aqueous phase over 3 min and
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held there to re-equilibrate the column. The mass range for collecting the scans was dependent on
the parent mass fragmented. Fragmentation was produced by ion collisions with nitrogen or argon.
Collision product ions were then analyzed by time-of-flight MS and a composite spectrum for the
2 min of fragmentation spectra were obtained. Fragmentation at different collision energies was
also carried out until fragment ion coverage was as complete as possible. As one spectrum was
collected per second, 120 MS/MS spectra were collected in 2 minutes and the MCA (multi-channel
analyzer) function was turned on which summed all 120 MS/MS spectra resulting in increased
signal to noise. The MCA spectra for different energies were overlaid together using the ‘overlay’
feature, followed by summing of all these spectra using the ‘sum overlays” feature to provide a
single spectrum with optimal fragmentation coverage.

The summed spectrum was visually inspected and compared to the exported peak list to
check for any miss-assigned charge states. After charge state correction, all the peaks in the peak
list higher than +2 were transformed into their +1 m/z values using the formula: +1 mass = m/z
value * charge – (charge – 1H+) to simplify the database search. The corrected mass list was
exported

as

a

tab-delimited

text

file

and

submitted

to

Mascot

(Mascot

2.3,

www.matrixscience.com) database search.

2.3.6 De Novo Sequencing of Protein or Peptide Markers
In instances when Mascot database comparisons of candidate marker MS/MS spectra did
not yield any promising results, de novo sequencing of these markers was attempted. MS/MS
spectra were first examined for b1 and/or y1 ions to indicate the start of the peptide sequence at
either the N- or C-terminus. These ions occur in the lower m/z range of the spectra. Peak
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comparisons were then made in an attempt to identify sequential amino acids. This process was
continued until a continuous chain of amino acid sequence was determined. The predicted peptide
sequences were also confirmed by independently subjecting them to a BLAST search available
through NCBI website which gave possible parent proteins for a peptide.

When a complete sequence of contiguous amino acids representing b- or y-series ions
cannot be obtained, sometimes the parent protein can still be determined. In general a sequence
of at least 5-6 consecutive amino acids must be identified before the parent protein can be
determined by comparison to a protein data base.

2.3.7 Mass Spectrometric Fragmentation and Manual Chemical Characterization of Lipid
Markers
In addition to protein or peptide biomarkers, several potential biochemical markers were likely
lipids based on their elution in the hydrophobic region of the cLC chromatogram. These candidates
were also submitted to MS fragmentation studies. The fragmentation data were reviewed for peaks
characteristic of some lipid classes, including the frequently seen peak at m/z 184.07 known to
represent a phosphocholine head-group 22-23.

Accurate mass determination of lipids was compared to the LIPID MAPS database
(http://www.lipidmaps.org/) to find archived lipids having very similar masses. LIPID MAPS MS
prediction tool (http://www.lipidmaps.org/tools/index.html) was also used to predict possible
fragments representing Sn1 and Sn2 acyl losses, which was then compared to actual peak masses
present in MS/MS spectra to identify possible fatty acid constituents. Additionally, previously
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reported MS/MS fragment assignments for glycerophosphocholines (PC) were used to confirm
identities of some candidate PC biomarkers based on comparable MS/MS spectra.

2.3.8 Evaluating Possible Lipid Dimer Formation of During ESI
Some observed marker peaks were consistent with the presence of lipid homodimers
(dimers of the same two PC species presenting as 2M+H+) or heterodimers (dimers of two different
PC species presenting as M1+M2+H+). To assess whether lipid dimers were formed using our
instrument, a lyso PC standard, 1-oleoyl-sn-glycero-3-phosphocholine, having a MW of 521.67,
was used (Sigma Aldrich). It was diluted with acetonitrile to a concentration of 12 µM followed
by addition of 88% formic acid (20 µL per 1 mL sample) and was directly infused into the ESITOF MS at a flow rate of 10 µL/min.

2.4 Results
The question addressed by this study was whether there were biomarkers observable in the serum
of pregnant women predictive of PE development later in the same pregnancy. To assess this, a
novel serum proteomic approach was used to interrogate the low abundance, LMW proteins,
peptides and other biomolecules. The approach found more than 60 candidate biomarkers that
were statistically or near statistically different in pregnant women sampled at 12-14 weeks
gestation who developed PE weeks to months later compared with pregnant women sampled at
the same time who had uncomplicated, term pregnancies. Enough specimen was available to
conduct MS/MS fragmentation studies on 39 of these.
summarized in Table 2.2.
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These candidate biomarkers are

Table 2.2 Statistically significant potential biomarkers
S No.
1
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.

m/z
942.5
571.3
593.3
619.8
1238.5
539.6
676.7
568.8
1071.4
601.3
649.3
509.3
569.3
621.4
723.47
767.5
503.3
508.3
513.3
553.3
594.3
665.4
697.4
739.4
975.6
1015.6
1026.6
1069.7
1074.6
1111.7
639.38
634.39
634.39
756.5
1540.1
1516.1
718.8
719.2
734.8

P value
0.017
0.005
0.034
0.03
0.03
0.05
0.02
0.05
0.05
0.012
0.00003
0.001
0.004
0.03
0.02
0.03
0.02
0.0002
0.003
0.0001
0.02
0.006
0.007
0.0003
0.0009
0.01
0.0001`
0.05
0.0005
0.08
0.0001
0.003
0.002
0.01
0.03
0.01
0.001
0.05
0.000003

Higher in
Controls
Controls
Controls
Controls
Controls
Cases
Cases
Cases
Cases
Controls
Cases
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Cases
Controls
Controls
Controls
Controls
Controls
Controls
Cases
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Cases
Controls
Cases
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AUC
0.611
0.585
0.583
0.566
0.562
0.177
0.477
0.505
0.242
0.647
0.636
0.693
0.67
0.568
0.519
0.502
0.573
0.748
0.674
0.753
0.589
0.628
0.637
0.809
0.698
0.021
0.769
0.514
0.7
0.5
0.79
0.675
0.707
0.613
0.574
0.629
0.591
0.612
0.705

2.4.1 MS Structural Characterization of PE Peptide Biomarker Candidates
Fragmentation studies on the 39 peaks suggested that 9 candidates were peptides based on higher
charge states, earlier elution times and fragmentation patterns consistent with a peptide, e.g.
presence of an immonium ion. Of these, 6 were identified using MS-MS fragmentation data, which
provided complete or near complete b- and y-series fragment ions and were identified by
MASCOT. Some were not identified by MASCOT because of high charge state (z > 3+), but were
identified by de novo sequencing. Among the 6 peaks identified, two sets of peaks represented the
same peptide found in different charge states. Hence, 4 unique peptides were successfully
sequenced.

The peptide with m/z 942.6 was identified as being a fragment of complement C3. The
peptides m/z 1070.8 and m/z 676.7 were found to be fragments of inter-alpha-trypsin inhibitor
heavy chain H4 isoform 2. Furthermore, peptides m/z 676.7 and 1014.5, were identical fragments
of the same protein with different charge states, where 676.7 was in the +3 form and 1014.5 was
the +2 form. Finally, the peptide with m/z 1238.5 was identified as being a fragment of βfibrinogen with a pyro-glutamic acid modification on its N terminus representing a glutamine or
glutamate. These are summarized in Table 2.3.

As indicated, 3 biomarkers that were likely to be peptides were not identified. This was
due to some combination of the following: high charge state, the inability to identify y1 or b1 ions,
higher MW (e.g. 40+ amino acids) coupled with low abundance leading to incomplete b- and yion series and in all instances inadequate specimen to carry out fragmentation studies at multiple
collision energies.
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Table 2.3 Amino acid sequence of peptide biomarkers and elemental composition and class for lipid
biomarkers successfully fragmented
m/z
charge MW
sequence/structure
parent protein/
Elemental
compound/class
composition
942.5

1

941.5

hwesasll

Complement C3

1070.8

4

4279.25

nvhsagaagsrmnfrpgvlss
rqlglpgppdvpdhaayhpf

Inter-alpha-trypsin inhibitor
heavy chain H4

676.7

3

2026.98

qlglpgppdvpdhaayhpf

Inter-alpha-trypsin inhibitor
heavy chain H4

1014.5

2

2026.98

qlglpgppdvpdhaayhpf

Inter-alpha-trypsin inhibitor
heavy chain H4 isoform

619.8

2

1237.5

pyro-egvndneegff

Beta-fibrinogen

1238.5

1

1237.5

pyro-egvndneegff

Beta-fibrinogen

756.6

1

755.6

PC(18:2/16:1)

1-(9Z,12Zoctadecadienoyl)-2-(9Zhexadecenoyl)- glycero-3- [C42H78NO8P+
H+]
phosphocholine

508.3

1

507.3

PC(O-18:1)

1-(11Z-octadecenyl)-snglycero-3-phosphocholine

594.3

1

593.3

PC(16:0/5:0(CHO))

1-hexadecanoyl-2-(5oxovaleroyl)-sn-glycero-3phosphocholine

1069.7

1

1068.7
(m/z
524.35 +
m/z
546.35)

1516.1

1

[C26H54NO6P+
H+]

[C29H56NO9P+
H+]

Dimer of LPC (18:0) + Glycerophosphocholines
LPC (20:3)
[C26H54NO7P+
C28H52NO7P] +
H+

1515.1
Dimer of PC(34:2) + Glycerophosphocholines
(m/z
PC(34:2)
758.6 +
m/z
758.6)
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[C42H80NO8P+
C42H80NO8P] +
H+

1540.1

1111.7

1015.7

975.7

1

1

1

1

1539.1
(m/z
758.57 +
m/z
782.57)
1110.7
(m/z
544.3 +
m/z
568.34)
1014.7
(m/z
496.35 +
m/z
520.35)

Dimer of PC(34:2) + PC Glycerophosphocholines
(36:4)

Dimer of LPC (20:4) + Glycerophosphocholines
LPC (22:6)

Dimer of LPC (16:0) + Glycerophosphocholines
LPC (18:2)

974.7
Dimer of LPC (O-16:1) Glycerophosphocholines
(m/z
+ LPC (16:0)
480.35 +
m/z
496.35)

[C42H80NO8P
+C44H80NO8P] +
H+
[C28H50NO7P+
C30H50NO7P]+
H+
[C24H50NO7P+
C26H50NO7P]+
H+

[C24H50NO6P+
C24H50NO7P]+
H+

634.4

1

633.4

Glycerophosphocholines

[C33H64NO8P]+
H+

1026.7

1

1025.7

Glycerophosphocholines

[C51H98N2O16P]
+ H+

513.3

1

512.3

Sphingolipids

[C24H53N2O7P] +
H+

553.3

1

552.3

Sphingolipids

[C25H49N2O9P] +
H+

509.3

1

508.3

Sphingolipids

569.33

1

568.3

Sphingolipids

593.3

1

592.3

Sphingolipids

[C29H49N2O7P] +
H+

Note: for candidate m/z 509.3 it was likely that this was a unique and unusual distinct sphingomyelin whose
fatty acid constituent could not be identified based on its fragmentation spectrum. Also, for candidate m/z
593.3 the elemental composition could not be determined because exact mass studies could not be
performed due to its very low abundance in the samples and limited samples.
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This group included the following additional markers (represented by their m/z ratio): 718.8,
719.2, and 734.8.

2.4.2 MS Structural Characterization of PE Lipid Biomarker Candidates
Several of the candidates did not appear to be peptides based on elution time, m/z and
fragmentation. This pattern included no evidence of immonium ions, no fragments with intervals
consistent with amino acids or modified amino acids but fragment features consistent with known
lipid classes, e.g. a peak at m/z 184.07 consistent with a phosphocholine head group.

2.4.2.1 Identified PE Lipid Biomarkers
Several of the lipid biomarkers were successfully categorized as phospholipids. The markers with
m/z 756.5, 594.3 and 508.3 were identified respectively to be glycerophosphocholine (PC) with
fatty acyl groups represent a 16 carbon fatty acid with one double bond (16:1) and an eighteen
carbon fatty acid with two double bonds (18:2), a lyso-PC (18:1) and an oxidized PC
(16:0/5:0(CHO)). Several species, m/z 1069.7, m/z 1026.7, 1516.1, 1540.1, 1111.7, 1015.7 and
975.7 were found to be dimers containing two copies of a single PC or coupling of two different
PC species (Table 2.3).

The MS-MS fragmentation spectrum for a number of other candidate markers, i.e. those
having m/z ratio of 634.4, m/z 513.3, m/z 553.3, m/z 509.3, m/z 569.3 and m/z 593.3 displayed a
prominent peak at m/z 184.07 indicating the presence of a phosphocholine moiety. Their elemental
composition was determined based on exact mass studies. However, their complete structure could
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not be determined. According to the nitrogen rule, the M+H+ even m/z (having odd neutral mass)
should correspond to the presence of odd number of nitrogen atoms.

Likewise, the odd M+H+ m/z (having even neutral mass) should represent even numbered nitrogen
atom containing species. Therefore the markers with m/z 634.4, 1026.7 are likely
glycerophosphocholines, while the markers with m/z 513.3, m/z 553.3, m/z 509.3, m/z 569.3 and
m/z 593.3 are likely to be sphingomyelins (Table 2.3).

A number of the other biomarker candidates were likely to be lipids, but did not belong to
identifiable classes of lipids, i.e. they lacked identifiable head groups or other recognizable
constituents and the fragmentation pattern, however detailed, remained uninterpretable using the
latest data bases and software. These included those species having m/z values of 639.4, 739.4,
503.3, 601.3, 649.3, 621.4, 665.5, 697.4, 571.3, 568.8, 539.6, 723.5, 767.5 and 509.3.

2.4.3 Biomarker Panel Development
As shown in Figure 2.1, the best single marker having m/z=739.4 provided an area under the curve
(AUC) of 0.809, and a sensitivity of 79% at a specificity of 67%. Statistical analyses were further
performed on potential markers to determine multi-marker models with better predictive values.
Only those 39 species submitted to fragmentation and having some chemical characterization were
used in multi-marker modeling. Several combinations were formed having an AUC > 0.9 as
summarized in Table 2.4. Furthermore, statistical analysis limited to just those biomarkers with
clear chemical identities or classifications yielded three combinations of
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Figure 2.1 ROC curve for the single best serum PE marker having an m/z 739.4.
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Table 2.4 Multi-marker panels constructed from combinations of the 39 biomarkers for which we
have fragmentation and classification data. Only the 6 top sets with their respective ROC curve
AUC values are shown
m/z
AUC
619.8, 739.4, 649.3, 1111, 756.5, 723.47

1

734.8, 639.38, 975.6, 756.5, 571.3, 568.8

1

785.5, 739.4, 649.3, 503.3, 639.38, 756.5, 676.7

1

639.38, 734.8, 975.6, 756.5, 571.3, 568.8

1

568.8, 734.8, 719, 718, 593.2, 1026.6, 503.3

0.99

1111, 639.8, 649.3, 509.3, 1516.1, 665.4,

0.98
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markers with AUC > 0.8 (Table 2.5). The ROC curve for the panel of identified markers (m/z
508.3, 594.3 and 756.5) having an AUC of 0.832 is shown in Figure 2.2.

2.4.4 Dimer Formation for Glycerophosphocholines
When a lyso-PC standard was directly introduced by ESI onto the MS system a small amount of
dimer was formed (See Figure 2.3). The peak at m/z 522.35 (ion count 270000) represented the
monoisotopic peak (M+H+) for the standard and the peak at m/z 1043.7 (ion count 32000, 11.8%)
corresponded to the homodimer of the same (2M+H+, m/z 1516.1). Table 2.6 represents the
intensities of the PC and its dimer in 5 samples.

2.5

Discussion

Preeclampsia is a serious, life-threatening complication of pregnancy whose cause is incompletely
understood. Currently, there is no effective way to predict who will likely develop PE during a
given pregnancy. Yet, the very possibility of developing this complication has contributed
substantially to the almost universal surveillance of pregnant women over the second half of their
pregnancies. Several biochemical and hemodynamic abnormalities accompany established PE,
but none have been shown to be useful in its prediction. The inability to accurately predict the
disease has made trials of pharmacologic agents to prevent or reduce the incidence of PE large and
expensive. This study sought to find predictive serum biomarkers of PE.

This approach found over 60 novel molecular species that were statistically or near statistically
different between cases and controls but only 39 of these could be characterized due to limited
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Table 2.5 Multi-marker panels limited to just the 7 identified markers. Lipid dimers and other
lipids where the fatty acid constituents could not be unequivocally identified were excluded. Only
those combinations that resulted in ROC curves having an AUC > 0.8.
m/z of panel of markers

AUC

Sensitivity

508.3, 594.3, 756.5

0.832

88%

70%

508.3, 594.3, 942.5

0.812

67%

79%

508.3, 594.3, 942.5, 1014.5

0.810

80%

70%
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Specificity

Figure 2.2 ROC curve for the best multi-marker panel found using just the 7 serum PE biomarkers
that have been effectively identified.
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Table 2.6 Abundances for a dimer marker (m/z 1516.1) and its monomer (m/z 785.5) in some of the
samples
Sample

Abundances for m/z
758.57

Abundances for m/z
1516.1

Ratio

1

8617

3296

2.6

2

9314

4258

2.1

3

9463

5236

1.8

4

9521

4008

2.2

5

9627

5753

1.7
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Figure 2.3 Direct infusion spectrum for the lyso-PC standard m/z 522.3 and the appearance of an
m/z 1043.7 representing its dimer
.This represents ~12% conversion of this lipid to its dimer under in vitro conditions described in
Methods.

75

specimen availability. Modeling experiments found 14 multi-marker panels with AUCs of 0.90
or more that appeared to be effective in identifying most pregnant women who would develop PE
in the same pregnancy. It is recognized that these statistics were developed on a small number of
samples and will work less well in a larger, unselected population of pregnant women.
Nevertheless, the results suggest that the method is robust, with its ability to survey routinely
~7000-8000 low molecular weight species and able to find candidate predictive biomarkers at 1214 weeks gestation. Clearly, other follow-up studies will be needed to verify these findings.

This approach has the additional advantage of allowing for the seamless transition from
discovering potential biomarkers to their further chemical characterization as part of tandem MSMS fragmentation studies. Identification methods for peptides and small proteins are much more
highly developed than approaches for characterizing lipids. Not surprisingly, most peptides were
identified. Two peptides (m/z 718.8, m/z 719.2) that were not sequenced had high charge states
(z = +6) making fragmentation data search engines useless and with their low abundances in MS1,
longer length (40+ amino acids), and very limited sample made de novo sequencing incomplete
without a clear identification. A third peptide was unsuccessfully characterized (m/z 734.4, z =
+2). This was a result of having no additional sera with sufficient levels of the peptide to complete
all of the several fragmentation studies that would have been necessary.

Among the 4 peptides identified, peptides m/z 942.6 and m/z 1238.5 were found to be
higher in controls and are fragments of the parent proteins complement C3 and beta-fibrinogen
respectively. Decreased levels of fibrinogen in PE pregnancies due to extensive platelet activation
and consumption as compared to uncomplicated pregnancies have been reported by others
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24-25

.

The biological activity or role of peptide fragments of fibrinogen in PE, if any, has not been
investigated. Likewise, activation of the complement system, resulting in depressed levels of
complement C3 in PE patients, has also been documented, but, again the possible activity or
biology implications of this fragment has not been explored 26-27. Both the peptides with m/z 676.7
and 1070.8 were found to be elevated in PE cases and belonged to the same parent protein, interalpha trypsin inhibitor heavy chain 4 (ITIH4), a kallikrein-sensitive acute phase reactant found to
be elevated in inflammatory states 28. Peptide m/z 676.7 has earlier been shown to be depressed
in sera of women at 24 weeks of pregnancy who suffered from early labor and subsequent
spontaneous preterm birth29.

As part of this study, several candidate biomarkers were found to be lipids. Marker m/z
508.3 was identified to be a lyso-phosphatidylcholine (lyso-PC). It was found to be lyso-PC (18:1)
and was higher in controls. Some studies suggest that phospholipases, especially phospholipase
A2, may be increased in the setting of PE 30. However, most of these phospholipases are cytosolic
enzymes and less likely to affect extracellular lipid levels. Consequently, there is not a particular
pathway known to be altered in PE for circulating lipids or the production of lyso-phospholipids
specifically. The peak having m/z 756.5 was shown to be a glycerophosphatidylcholine (PC)
(16:1/18:2) and was higher in women having uncomplicated pregnancies. The lipid having m/z
594.3 was

found to

be higher in

PE cases and appears to be an oxidized

glycerophosphatidylcholine, in which one of the fatty acyl chains is oxidized to an aldehyde group.
The compound appears to be 1-hexadecanoyl-2-(5-oxovaleroyl)-sn-glycero-3- phosphocholine. It
has been previously demonstrated that PC species if exposed to reactive oxygen species (ROS)
can undergo an aldehyde modification 31. There have been several reports of increased ROS in PE
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and this association might explain the increased levels of this species in PE cases as compared to
controls 32-33.

Several of the lipids were characterized and found to be lipid dimers composed of two
glycerophosphatidylcholines. The two PCs were not simply associated with each other but were
covalently linked. Those that could be more completely characterized as lipid dimers included
lipids with m/z = 1069.7, 1015.7, 975.7, 1111.7, 1516.1, 1540.1, 1026.7 and 1074.7. The source
of these lipid dimers remains unclear. There are some previously publications suggesting that
these may be formed as a result of the ionization process in the ESI source

34-35

. The extent of

dimerization by ESI under the conditions used for these studies was probed by submitting a PC
standard of known composition to direct injection on the ESI-TOF-MS system, albeit at a higher
concentration than observed for any of the lipids found endogenously. The dimer (m/z 1516.1) of
the standard was observed (Fig 2.3) but dimerization, even with high concentrations was ~12% of
the standard added. In contrast, the abundance of lipid dimer observed at m/z 1516.1 in several
actual serum samples was found to be ~2 times greater than that of the monomer at m/z 758.5
(Table 2.6). This suggests that the great majority of this dimer and presumably others is produced
in vivo, perhaps through free radical exposure. However, the possibility of non-biological
production of dimers during the ionization cannot be ruled out.

While no other group has carried a global (or shotgun) proteomic study of lower molecular
weight PE biomarkers, many other groups have worked to develop useful biomarkers for PE
focused on a single target or a few molecular species (including some MS approaches), and a few
appear to have good AUC values and high detection rates in initial studies
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13

. For example, an

AUC value of 0.7 was reported for pregnancy associated plasma protein-A (PAPP-A) in predicting
PE when measured in the first trimester 36. Nevertheless, the AUC and PE detection rates observed
in our study exceed previously reported values and at a minimum represent complementary tests
that could enhance early PE testing. Relying on a single marker to predict all PE may not be
possible and not surprisingly, there are no currently clinically accepted prognostic biomarkers for
PE. We believe that a more global approach is needed to overcome these limitations. It is likely
that a combination of markers that detect PE of different etiology, severity, genetic factors will
prove better for the purpose of pre-symptomatic detection of pregnant women at risk for PE. Even
in what seems to be a somewhat homogenous population, PE still presents a spectrum of disease
severity, timing, complications and in different populations, e.g. obese versus lean women, there
are likely to be other biochemical differences leading to different proteomic profiles. Hence, more
inclusive multi-maker panels are likely to be more predictive of PE generally, reflecting possible
differences in etiology or involving different pathologic pathways that produce the diagnostic PE
phenotype. As such, biomarkers representing biologically diverse pathways would likely then
provide better overall coverage.

2.6 Future Perspective
These results appear promising with many novel candidate serum biomarkers discovered
and many effective combinations developed providing potentially valuable risk assessment of PE.
Future studies will need to retest and validate these candidate markers in independent specimens
from different populations with laboratory analysis carried out absent knowledge of case or control
status. This will require accumulation of or access to similarly timed specimens, processed
expeditiously to allow for similar results and not submitted to freeze-thaw cycles. If the markers
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are shown to be valid over time and considered useful in the screening of pregnant women, the
MS method could be scaled up (as was done for the preterm labor marker fetal fibronectin 37) to
service high numbers of specimens.

Alternatively, individual high throughput assays, e.g.

immunoassays, could be developed for several of the best markers as is done for other clinical
assay panels (lipids, cardiovascular risk factors, etc). Also, these markers themselves suggest
biochemical changes occurring early in the pregnancies of women who will develop PE many
weeks later. Further studies of these suggested pathways or processes, e.g. ROS, would be helpful
in more fully explaining or verifying very early pathologic changes leading to PE. Having useful,
verified biomarkers that predict later PE would allow for far smaller clinical studies, including
evaluation of pharmacologic or other medical treatments for this potentially fatal disease.
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Chapter 3

Detection and Confirmation of Serum Lipid Biomarkers for Preeclampsia
Using Direct Infusion Mass Spectrometry

Disclaimer- This chapter is mainly reproduced from a manuscript officially accepted by Journal
of Lipid Research. Swati Anand, Sydney Young, Sean M. Esplin, Benjamin Peaden, H. Dennis
Tolley, T. Flint Porter, Michael W. Varner, Mary E. D’Alton, Bruce Jackson, Steven W. Graves

3.1 Abstract
Despite substantial research, the early diagnosis of preeclampsia remains elusive. Lipids are now
recognized to be involved in regulation and pathophysiology of some disease. Shotgun lipidomic
studies were undertaken to determine if serum lipid biomarkers exist that predict preeclampsia
later in the same in pregnancy. A discovery study was performed using sera collected at 12-14
weeks pregnancy from 27 controls with uncomplicated pregnancies and 29 cases that later
developed preeclampsia. Lipids were extracted and analyzed by direct infusion into a time-offlight mass spectrometer.

MS signals, demonstrating apparent differences were selected, their

abundances determined and statistical differences tested. Statistically significant lipid markers
were reevaluated in a second confirmatory study having 43 controls and 37 preeclampsia cases.
Multi-marker combinations were developed using those lipid biomarkers confirmed in the second
study. The initial study detected 45 potential preeclampsia markers. Of these, 23 markers
continued to be statistically significant in the second confirmatory set. Most of these markers
representing several lipid classes were chemically characterized typically providing lipid class and
potential molecular components using tandem MS. Several multi-marker panels with AUC>0.85
and high predictive values were developed. Developed panels of serum lipidomic biomarkers
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appear able to identify most women at risk for preeclampsia in a given pregnancy at 12-14 weeks
gestation.

3.2 Introduction
Preeclampsia is a potentially life-threatening disorder of pregnancy characterized by newonset hypertension and proteinuria after 20 weeks gestation. It constitutes a leading cause of
maternal and perinatal mortality and morbidity1-2. Estimates are that as many as 75,000 women
worldwide die each year from preeclampsia3. Treatment options are very limited and frequently
require termination of the pregnancy, regardless of gestational age, accounting for ~20% of all
preterm births4. Furthermore, infants born to preeclamptic mothers may be at an increased risk of
hypertension, heart disease and diabetes beyond their being premature5.

While there are known risk factors for preeclampsia, it is not yet possible to precisely
distinguish pregnancies destined to develop preeclampsia from those that will not. This has made
prospective clinical studies large and expensive. Also, it has to some degree limited studies of
early changes that may lead to preeclampsia. In the absence of a complete animal model of
preeclampsia, the actual cause or causes of this disorder remains unknown. The pathogenesis is
acknowledged to be complex and although incompletely understood, it is generally believed that
one or more very early events in the pregnancy contribute to preeclampsia. One long held theory
to explain this disease involves an incomplete remodeling of maternal spiral arteries by invasive
extravillous placental trophoblast cells resulting in inadequate perfusion of the fetal-placental unit
with attendant ischemia6-7. Abnormal waveform patterns and an increased pulsatility index
observed in uterine Doppler ultrasound studies support the concept of an underperfused fetus prior
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to clinically apparent preeclampsia6-7. There is also evidence to suggest that biochemical changes
may be seen in women who, later in the same pregnancy, develop this disease. Several other
biochemical changes appear to precede by a few weeks clinically evident preeclampsia, including
hypoxia-reoxygenation8, abnormal expression of angiogenic and anti-angiogenic factors in the
maternal circulation and endothelial dysfunction with a pro-inflammatory response9-10.
Collectively, these data suggest that there are biochemical abnormalities that occur prior to
clinically evident preeclampsia signs and symptoms. However, to date there are still no accepted,
predictive biomarkers for this disease11-13 despite some initial promise for a number of proposed
candidates. Also currently, the specific causes (as opposed to consequences) of preeclampsia are
still debated and have yet to be established.

It is now possible to survey hundreds to thousands of molecules in biological specimens in
an unbiased way using mass spectrometry (MS). Proteomics is by far and away the most common
of these approaches and has been employed to study several diseases, but its use to explore
diagnostic or predictive biomarkers in serum is difficult due to ~30 highly abundant serum proteins
that mask the vast majority of lower abundance species in serum due to ion suppression. Other
methods have targeted peptides and lipids, although much less frequently in serum or plasma.

Lipids are increasingly recognized as having important biological roles or representing
important biochemical correlates of clinical changes. A wide variety of human diseases are
associated with aberrant lipid metabolism including Alzheimer’s disease, diabetes and
atherosclerosis14-16. Alterations in lipids may represent by-products of underlying pathophysiology
but could also represent primary disease mediators. For example, arachidonic acid is a precursor
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for eicosanoids that have a significant role in inflammatory processes. There is evidence of
changes in downstream products of arachidonic acid in preeclampsia17. As another example,
oxidized lipid species can reflect increased reactive oxygen species (ROS) which are produced as
a part of several diseases18-20. Therefore, there is ample reason to study lipid profiles in pregnant
women at an early stage seeking predictive lipidomic biomarkers to identify patients at significant
risk for preeclampsia. Consequently, a ‘global’ serum lipidomic approach, involving lipid
extraction followed by direct injection, time-of-flight mass spectrometry was used to identify and
chemically characterize predictive serum preeclamptic lipid biomarkers. We hypothesized that this
approach would find individual lipids and sets of lipids that would allow for the prediction of a
substantial portion of women who would later develop this disease in the same pregnancy and that
the changes would provide insights into the mechanisms early in the development of preeclampsia.

3.3 Methods
3.3.1 Study population

Serum specimens used for both the discovery and confirmatory studies were obtained from
the Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake
City, UT and from Intermountain Health Care (Intermountain), Murray, UT. All samples were
banked sera, obtained from a previously completed clinical study, “First- And Second-Trimester
Evaluation of Risk”21. Institutional Review Board (IRB) approval for these studies was obtained
from the University of Utah, Intermountain and Brigham Young University prior to our initiating
these experiments. Sera had been collected from pregnant women at 12-14 weeks gestation
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followed through the completion of their pregnancies. Specimens were analyzed without clinical
identifiers.
A discovery cohort involved sera from 27 controls, having term, uncomplicated
pregnancies and 29 cases, who developed preeclampsia later during the index pregnancy. The
second confirmatory study of the promising potential lipid biomarkers from the discovery cohort
involved serum from 37 cases and 43 controls, also collected at 12-14 weeks gestation.
Demographic characteristics are summarized in Tables 3.1 and 3.2.

3.3.2 Materials
Glycerophosphocholine lipid standards: PC (14:0/16:0) and PC (18:0/18:2) were purchased from
Avanti Lipids (Alabaster, AL, USA). A triacylglycerol standard: TG (16:0/18:0/16:0) was
purchased from Sigma Aldrich (St. Louis, MO, USA).

3.3.3 Sample preparation
All specimens had been stored at -800C until our receiving them on dry ice and were maintained
at -80oC before and after sample processing. Serum lipid extraction efficiency of five different
organic extraction solutions were performed as follows: for a 200 µL sample 1) 2.5 mL of 4:1
chloroform:methanol; 2) 2.5 mL of 4:1methyl-tert-butyl ether:methanol; 3) 1.8 mL of 3:2
hexane:isopropanol; 4) 2.3 mL of 3.6:1hexane:methanol; or 5) 2.0 mL of 3:1benzene:methanol.
Of these the procedure producing both the highest number of MS features and best signal to noise
was chosen for use here. This was a modified, previously described extraction protocol that
involved a solvent mixture of hexane: isopropanol (3:2)22. To 200 µL of serum, 1.8 mL hexane:
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Table 3.1 Demographics for the First, Discovery Study
Maternal
age (yrs)

Gestational BMI
age (wks)
(kg/m2)

SBP

DBP

Birthweight
(gm)

Race

Cases

30 ± 4.6

36.4 ± 3.07 30.8± 5.42

149.5± 17.4

90.1± 12.3

2755 ± 801

28/29 Cau

Controls

27 ± 4.8

39 ± 1.23

138.6± 14.7

80 ± 12.5

3459 ± 349

27/27 Cau

30.4 ± 5.6

Note: BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; Cau =
Caucasian
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Table 3.2 Demographics for the Second, Confirmatory Study
Maternal Gestational BMI
SBP
age (yrs) age (wks)
(kg/m2)

DBP

Birthweight
(gm)

Race

Cases

29 ± 4.7

36.3 ± 3.2

31.7 ± 5.89

147 ± 20.8

90 ± 15.1

2817 ± 860.9

37/37 Cau

Controls

26 ± 4.7

38.7 ± 1.6

27.9 ± 4.7

117 ± 14.4

70.4 ± 8.2

3295 ± 535.2

43/43 Cau

Note: BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; Cau =
Caucasian
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isopropanol (3:2) and 300 µL of 0.5 M KH2PO4 were added in a glass tube followed by vigorous
vortexing. Samples were further agitated on a shaking platform for 1 h at room temperature at the
speed of 80 rpm. To complete the extraction, 150 µL of water were added, mixed and centrifuged
at 2000 rpm for 12 min. The upper, organic phase containing lipids was collected and dried
completely under nitrogen. Dried lipid extracts were redissolved in 200 µL of chloroform:
methanol (3:1) and stored at -80 0C.

3.3.4 Mass spectrometric analysis of the lipid extract
To a 20 µL aliquot of the sample extract, 23 µL of chloroform, 46 µL of methanol and 14 µL of
12 µM ammonium acetate were added. The samples were directly injected into the mass
spectrometer (6230 TOF LC/MS Agilent Technologies) through an electrospray ionization (ESI)
source operated in the positive ion mode. A syringe pump was utilized to inject samples at the flow
rate of 2 µL/min. The ESI source employed a microspray needle having an i.d. of 50 µm. The
capillary voltage was set at 3500 V. MS data was collected over mass to charge ratios (m/z) of
100-3000 with an acquisition rate of 1 spectrum/sec. Nebulizer gas and dry gas parameters were
optimized to obtain a stable flow. The dry gas was set to 5 L/min at 3250C with a nebulization gas
pressure of 1.03 bar. Mass Hunter-Qualitative software [Agilent Technologies] was used for data
analysis. Each specimen generated a mass spectrum from which the total ion chromatogram (TIC
the sum of all ion counts) from m/z 100 to 3000 was determined. A peak list having m/z values for
all peaks with their abundances was generated from the mass spectrum.

To reduce analytical variability all MS peaks were normalized. For normalization, 7
abundant peaks representing different classes of lipids but showing similar abundance in both case
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and control sera (p>0.40) were chosen as a reference set and their abundances averaged. The m/z
values and classes for these peaks are as follows: m/z 203 (fatty acid), 369 (sterol), 666 (cholesterol
ester), 758 (phosphatidyl choline (PC)), 782 (PC), 810 (PC) and 848 (triacylglycerol). These peaks
were consistently seen in all the samples. The ratio of the average intensity of these 7 peaks was
comparable to or more consistent than the use of TIC counts for peak normalization, but avoided
the occasional high TIC for a few MS runs with a high background. Therefore, the average of the
combined intensity of these 7 peaks was used to normalize all peaks across the each individual
mass spectrum.

For the second confirmatory study, all the samples were processed using the same method
and were directly injected onto the same MS instrument at a flow rate of 10 µL/min, using a
standard sprayer having an i.d. of 120 µm. The microbore needle had previously been blocked on
several occasions. The larger bore needle used here eliminated that problem. The increased flow
rate and shorter run times kept the TIC, peak list and abundances comparable to the initial study.
All the other parameters were kept identical. All the potential significant markers from the initial,
discovery set were reanalyzed for their performance in the second confirmation set using Student’s
T-test.

3.3.5 Chemical characterization of the replicating lipid biomarkers
After candidate biomarkers were found and confirmed significant by ESI-TOFMS, tandem MS
(MS2) was performed to fragment and characterize all validated biomarkers. Lipid markers were
fragmented using a QSTAR Pulsar 1 quadrupole (Sciex, Framingham, MA) and as needed an
Agilent 6530 Q-TOF MS (Agilent, Santa Clara, CA) in the positive ion mode. For the QSTAR,
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samples were injected directly at a flow rate of 2 µL/min. The capillary voltage was set to 4200 V.
The selection of the mass range targeted for fragmentation depended upon the m/z of the precursor
ion with a spectral acquisition rate of 1 spectrum/sec. Declustering and focusing potentials were
set to 65 V and 290 V respectively. Nitrogen and/or argon gas was used for collisionally-induced
fragmentation.

Multiple fragmentation energies were employed to obtain as complete

fragmentation as possible. MS2 spectra were collected for 2 min and the multi-channel analyzer
(MCA) function was turned on resulting in summation of all 120 MS2 spectra together thus
increasing signal to noise ratio.

For the Agilent 6530, sample injection was carried out at the flow rate of 10 µL /min. The
capillary voltage was set to 3500 V. The drying gas flow rate and the temperature were 5 L/min
and 3000C. MS2 spectra were collected from m/z 50-3000 and the spectral acquisition rate was 3
spectra /sec. Collision energies were optimized depending upon the precursor to obtain maximum
fragmentation coverage. Individual scans were summed using the add feature of the Mass Hunter
program to obtain greater signal to noise. The targeted MS2 mode was used to isolate and fragment
the precursor ion.

Exact mass studies were done while using a set of internal standards. Lipidmaps.org was
used to tentatively determine the lipid class from the different possible classes for a particular
precursor ion. Furthermore, product ions, neutral losses, fragmentation patterns of standards or
fragmentation patterns found in the literature, in conjunction with predicted fragments from the
databases and predicted elemental compositions based on exact mass studies were compared with
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the actual observed fragments to determine the class and to evaluate the possible or probable
components of the individual candidate markers.

3.3.6 Statistical Analyses
For comparisons between the cases and controls, the normalized intensities of all the peaks
(abundance > 200 ion counts) in the first study were subjected to a two-tailed Student’s t-test as
an initial statistical comparison. A p-value <0.05 for any peak, was used to designate a potential
biomarker. It is recognized that since the t-test statistic was performed for multiple peaks,
separately, the true p-values are much larger than 0.05. Consequently, any candidate biomarker
potentially may not be statistically significant between the cases and controls. However, using a
one-at-a-time p-value calculation with a minimum threshold reduces the list of potential
biomarkers. We augment this list by adding peaks that had low p-values close to 0.05 but greater
than this threshold, resulting in a list of 45 potential biomarkers. Those peaks that continued to
show differential expression, as measured by a p-value of less than 0.05 as determined from a oneat-a-time t-test in the second, independent set of specimens were considered highly likely to be
biomarkers. Given the goal of generating panels of biomarkers, candidates with a p-value between
0.05 and 0.10 were also included because it is recognized that some markers may be selective for
a subgroup within the broader diagnosis of preeclampsia and hence may be complementary to
other markers. For this reason, they were considered in potential biomarker panels and were
modeled to provide better sensitivities and specificities. Biomarker panel development employed
a forward selection; leave one out, logistic regression analysis approach23-24. In modeling the MS
data, there were a few peaks in a small number of specimens for which intensities could not be
determined due either to ion suppression by other nearby peaks or because of a sub-threshold
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abundance of a specific peak in that sample. To account for these missing values, the values for
these peaks were estimated using multivariate imputation by chained equations. The method of
chained equations used to predict the missing values was through predictive mean matching. This
uses the values of the other samples to impute missing values, allowing for all peaks to still be
used25. Using logistic regression analysis receiver operator characteristic curves were generated
for these panels to allow for the determination of sensitivity (true positive) and specificity (1-true
negative or false positive rate).

3.4 Results
3.4.1 Serum lipid preeclamptic biomarkers in a discovery study
The hypothesis of this study was that there would be serum lipid biomarkers present at 12-14 wks
pregnancy predictive of preeclampsia later in the same pregnancy. Using a global, serum lipidomic
approach, the initial study of 27 controls and 29 cases found 45 candidate markers that were
statistically or near statistically different in women who developed the disease compared with
women who had uncomplicated pregnancies. The candidate markers are listed in table 3.3.

3.4.2 Replicating serum lipid biomarkers established in the second confirmatory study
A second confirmation study of the 45 candidate biomarkers was performed to evaluate their
performance in a second set of specimens processed and analyzed comparably. This set, also
collected at 12-14 wks pregnancy, involved 43 controls having uncomplicated term pregnancies
and 37 cases having preeclampsia later in the same pregnancy.
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Table 3.3 Candidate Preeclamptic Lipid Biomarkers

No.
1.
2.
3.
4.
5.
6.
7.`
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.

m/z
211.0
228.2
239.1
256.2
257.1
263.2
280.9
282.2
301.2
383.3
425.1
430.2
462.3
445.4
520.3
531.4
548.4
642.6
645.5
663.5
714.6
734.6
760.6
774.5
784.6
894.7
788.6
796.6
798.6
810.6
836.6
838.6
895.7
896.7
898.8
904.8
916.8
920.7
922.7
924.7
926.8
928.8
954.8
956.8
958.8

P value
0.1
0.07
0.06
0.08
0.07
0.08
0.04
0.08
7.1 X 10^-6
2.5 X 10^-8
0.08
0.05
0.05
3.4 X 10^-4
0.08
0.02
0.05
0.03
0.06
2.5 X 10^-5
0.009
0.07
0.08
0.04
0.05
0.02
0.06
0.09
0.03
0.1
0.1
0.07
0.02
0.02
0.02
0.08
0.01
0.009
0.001
0.003
0.005
0.006
0.01
0.004
0.005
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Higher in
Cases
Cases
Cases
Cases
Cases
Cases
Controls
Cases
Controls
Cases
Controls
Cases
Cases
Controls
Cases
Cases
Cases
Cases
Controls
Cases
Controls
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls

Of the 45 potential biomarkers, 23 continued to show a statistically significant or near significant
p-values when considered one at a time. These markers are listed table 3.4.

3.4.3 Multi-marker panel development
Statistical modeling, using logistic regression analysis, was performed on the 23 replicating
markers to develop multi-marker panels with higher predictive values. Several panels having
combinations of 3-6 markers were obtained demonstrating areas under the curve (AUC) >0.85 for
receiver operator characteristic (ROC) curves as illustrated in table 3.5. The ROC curves for two
multi-marker combinations having AUC of 0.89 (sensitivity ~91% at a specificity of ~82% and
the second ~86% and specificity ~81%) are shown in Figures 3.1 and 3.12. A plot showing the
classification of cases and controls by means of a panel of 6 markers, m/z 263.3, 383.3, 462.3,
645.5, 784.6 and 920.7 is shown in Figure 3.3. The overall AUC of this set is 0.88.

3.4.4 Chemical characterization of the validated serum lipid preeclamptic biomarkers
While absolute chemical structures of most lipids are not possible using MS, substantial chemical
characterization is often provided by tandem MS fragmentation studies. Tandem MS studies were
performed on all 23 confirmed serum lipid biomarkers. This provided lipid classes, exact mass
studies suggested possible or probable elemental composition and fragments representing neutral
losses suggested possible or probable structural components for most of the confirmed lipid
biomarkers. The molecular features most consistent with the data are described in Table 3.6.
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Table 3.4 Candidate Biomarkers that Continued to be Statistically Significant in the Second
Confirmation Study

S. No.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.

m/z
263.2
301.2
383.3
425.1
462.3
445.4
645.5
714.6
734.6
760.6
784.6
788.6
796.6
798.6
810.6
836.6
895.7
916.8
920.8
928.8
954.8
956.8
958.8

P value
0.07
0.005
0.05
7.8 X 10^-5
0.04
0.03
0.0001
0.008
0.1
0.06
0.005
0.08
0.06
0.06
0.007
0.06
0.009
0.003
0.003
0.05
0.003
0.003
0.0008
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Higher in
Cases
Controls
Cases
Controls
Cases
Controls
Controls
Controls
Cases
Cases
Cases
Controls
Cases
Cases
Cases
Cases
Controls
Controls
Controls
Controls
Controls
Controls
Controls

Table 3.5 Multi-Marker Panels with AUC > 0.85
AUC
0.89
0.89
0.89
0.88
0.86

Modeled Marker Combinations
263, 383, 445, 645, 784, 916
383, 462, 445, 645, 784, 810
383, 445, 784, 796, 798, 920
263, 383, 645, 784, 836
263, 383, 645, 784

100

Figure 3.1 Resulting receiver operator characteristic curve
generated by logistic regression analysis that included 6 lipid biomarkers having mass to charge
ratios of 383, 445, 784, 796, 798 and 920. The AUC was 0.89 with a sensitivity of ~91% at a
specificity of ~82%.
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Figure 3.2 Resulting receiver operator characteristic curve
generated by logistic regression analysis of another combination of 6 lipid biomarkers having mass
to charge ratios of 263, 383, 445, 645, 784 and 916. Some peaks are common to the two panels. The
AUC of this set was also 0.89 with a sensitivity of ~86% at a specificity of ~81%.

102

Figure 3.3 A plot showing the ability of a panel of 6 biomarkers, m/z 263.3, 383.3, 462.3, 645.5,
784.6, 920.7, to correctly classify cases and controls.
Controls are shown in blue and cases are displayed in red. Each point represents a different
patient. The overall AUC is 0.88 for this set of markers
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Table 3.6 Chemical Characterization of Preeclamptic lipid Biomarkers

m/z

Adduct

1

263.2

M+H+

Fatty alcohol and
aldehydes

2

301.2

M+H+

Fatty acids and
conjugates

3

383.3

M+

Oxidized
cholesterol

4

425.1

------

5

445.4

M+H+

6

462.3

-------

7

645.5

M+H+

Cholesteryl esters

C18:4 cholesteryl
ester

8

714.6

M+NH4+

Cholesteryl esters

C22:6 cholesteryl
ester

9

734.6

M+H+

Glycerophosphocholine

PC-32:0

16:0 and 16:0

10

760.6

M+H+

Glycerophosphocholine

PC-34:1

16:0 and 18:1

11

784.6

M+H+

Glycerophosphocholine

PC-36:3

18:1 and 18:2

12

788.6

M+H+

Glycerophosphocholine

PC-36:1

18:0 and 18:1

13

796.6

M+H+

Glycerophosphocholine

PC-O-38:4

14

798.6

M+H+

15

810.6

M+H+

Glycerophosphocholine

PC-38:4

18:0 and 20:4

16

836.6

M+H+

Glycerophosphocholine

PC-40:5

18:0 and 22:5

Class

Possible identity

-----------

----------

Cholesterol derivatives
------------

----------

Oxidized
Glycerophosphocholine
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PC-36:4+OH

O-18:0 and 20:4

16:0 and 20:4
+OH

17

895.7

M+H+

Oxidized sphingomyelin

18

916.8

M+NH4+

Oxidized triacylglycerol

19

920.7

M+NH4+

Triacylglycerol

20

928.8

M+NH4+

Triacylglycerol

21

954.8

M+NH4+

Triacylglycerol

22

956.8

M+NH4+

Triacylglycerol

23

958.8

M+NH4+

Triacylglycerol

OOOepoxide

TG-56:8

16:0, 18:2 and
22:6
LLL-monohydroperoxide
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Fragmentation results with any chemical structural information are summarized briefly for the
validated markers:
The biomarker m/z 263.2, when fragmented, demonstrated several hydrocarbon fragments in the
low m/z region consistent with its having an alkane region. This marker’s fragmentation pattern
was most consistent with that of a fatty alcohol or aldehyde. Its elemental composition of C18H30O,
as determined on LIPID MAPS indicates a fatty alcohol or aldehyde. This compound could also
correspond to an [acyl]+ ion for linoleic acid as reported previously26. A fragment ion at m/z 245.2,
predicted to result from the (linoleoyl-H2O)+ ion, was also observed26 in our MS2 studies of the
precursor m/z 263.2.The ions at m/z 263.2 and m/z 245.2 have also been observed in the MS2
spectrum of linoleic acid (m/z 298 for M+NH4+) in previous studies26. However, the occurrence of
m/z 263.2 corresponding to the (linoleoyl)+ ion was not observed in the MS1 spectrum in that report
indicating that m/z 263.2 is more likely to be a protonated fatty alcohol or aldehyde and not the
(linoleoyl)+ ion The marker with m/z 301.2 was predicted to have an elemental composition of
C20H28O2 consistent with its being a fatty acid or fatty acid conjugate.

Another marker having m/z 383.3 produced a fragmentation pattern consistent with it being an
oxidized (keto or epoxy) cholesterol27-28. The lipid ion peak at m/z 383.3 has been identified to be
dehydrated 7-ketocholestrol in a number of published studies involving human blood samples2931

, although, we recognize that oxidation of cholesterol at some other position is possible and

would result in similar fragmentation.

The species at m/z 445.4 was likely to be a cholesterol derivative as indicated by its
fragmentation pattern. Fragmentation studies for two other markers having m/z 645.5 and m/z
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714.6 resulted in a fragment ion at m/z 369.4, characteristic of cholesteryl esters, formed with
octadecatetraenoic acid (C18:4) and docosahexaenoic acid (22:6) respectively.

To improve interpretation of fragmentation data for glycerophosphocholine (PC) lipids,
studies were performed on a standard, PC (14:0/16:0). Figure 3.4a shows the MS2 spectrum of
protonated PC (14:0/16:0) having m/z 706.5 displaying a highly abundant signal at m/z 184.1
arising from the protonated phosphocholine moiety, characteristic of fragmentation of
lysophosphatidylcholines (LPC), PC and SM species32. Figure 3.4b displays the fragment ion at
m/z 468.3 corresponding to protonated LPC (14:0/0:0) and a fragment ion at m/z 496.3
corresponding to protonated LPC (16:0/0:0) resulting from the neutral losses of the fatty acyl
chains. The peak at m/z 523.4 (M+H-183)+ results from the loss of the entire phosphocholine head
group from the precursor at m/z 706.5. These are all predicted fragments. No other fragments
were seen for unpredicted truncations, combinations or any other unanticipated collision product.
We also performed MS2 studies on a second standard, PC (18:0/18:2) showing a protonated peak
at m/z 786.6. Its fragmentation spectrum displayed fragment ions at m/z 184, 520.3 and 524.3 (Fig
3.5a and 3.5b). The signal at m/z 184 corresponds to protonated phosphocholine whereas m/z 520.3
and 524.3 correspond to LPC (18:2/0:0) and LPC (18:0/0:0) produced by neutral losses of the fatty
acyl chains. Again, all fragments were exactly as predicted and no other fragments were observed.
Studies involving identification of PC’s based on the neutral losses of the fatty acyl chains are
commonly observed in literature33-35.
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Figure 3.4 MS2 spectrum for a glycerophosphocholine standard PC (14:0/16:0) with m/z 706.5
(M+H+). a) The abundant fragment ion at m/z 184 corresponds to the protonated phosphocholine
head group.b) The fragment at m/z 468.3 corresponds to protonated LPC (14:0/0:0). Similarly the
fragment at m/z 496.3 corresponds to protonated LPC (16:0/0:0). Neutral loss of the entire
phosphocholine head group leads to the formation of the ion at (M+H-183)+ at m/z 523.
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Figure 3.5 MS2 spectrum for a glycerophosphocholine standard PC (18:0/18:2) with m/z 786.6
(M+H+).a) The abundant fragment ion at m/z 184 corresponds to protonated phosphocholine head
group. Neutral loss of the entire phosphocholine head group leads to the formation of the ion at
(M+H-183)+ at m/z 603.5. b) The fragment at m/z 520.3 corresponds to protonated LPC (18:2/0:0).
Similarly the fragment at m/z 524.3 corresponds to protonated LPC (18:0/0:0).

109

Collectively, our study and published literature suggest strongly that fragmentation patterns
observed with PC lipid species follow predictable fragmentations.

Based on their fragmentation patterns, several of the lipid markers were categorized as PC
lipids. The MS2 fragmentation spectrum for markers with m/z values of 734.6, 760.6, 784.6, 788.6,
796.6, 798.6, 810.6, 836.6 and 895.7 displayed a prominent peak at m/z 184.07 corresponding to
a phosphocholine moiety. Their elemental compositions were predicted using exact mass studies
and the fatty acyl constituents were assigned based on the neutral losses from the precursor ion
with help from the lipid MS predictor feature from LIPID MAPS and following the fragment
patterns observed with PC standards.

The fragmentation spectrum of the marker with m/z 734.6 also displayed low abundance fragment
ion with m/z 496.3 suggesting the presence of 16:0 fatty acyl chain33 (Fig 3.6). Therefore, putative
structure for m/z 734.6 is likely to be PC (32:0) +H+ having two 16:0 fatty acyl chains. The MS2
spectrum of the marker with m/z 760.6 displayed fragment ion peaks at m/z 496.3 and m/z 504.3
consistent with the presence of 16:0 and 18:1 fatty acyl chains34. Therefore, this lipid m/z 760.6 is
likely to be PC (34:1)+H+. Similarly, markers with m/z 784.6, 788.6, 810.6 and 836.6 were
predicted to be PC (36:3)+H+, PC (36:1)+H+, PC (38:4)+H+ and PC (40:5)+H+ 34. Based on the
fragmentation patterns, the fatty acid components for these same markers m/z 784.6, 788.6, 810.6
and 836.6 were predicted to be (16:0 and 18:1), (18:0 and 18:1), (18:0 and 20:4) and (18:0 and
22:5) respectively34.
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Figure 3.6 MS2 spectrum for a lipid marker with m/z 734.5.
Fragmentation suggests that it is likely to be a protonated adduct of PC -32:0. The fragment ion at
m/z 496.3 is likely due to protonated LPC (16:0/0:0) resulting from the neutral loss of another 16:0
from the precursor ion.
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The MS2 spectrum of marker m/z 796.6 displayed a fragment ion at m/z 510.3 previously reported
to indicate the presence of an O-18:0 fatty acyl chain36. Based on the several fragments observed,
it is predicted to be PC(O-38:4) having a combination of O-18:0 and 20:4 fatty acyl chains
consistent with the previously published literature36.

The fragmentation spectrum of marker m/z 798.6 displayed a prominent fragment ion peak
at m/z 780.6 likely to result from water loss from the precursor ion and is not otherwise commonly
observed in the MS2 spectrum of PC’s. This major neutral water loss peak observed for this
precursor, suggests strongly an easily removable hydroxyl group37. A fragment ion at m/z 496.3,
most likely corresponding to 16:0 fatty acid, was also observed. This fragmentation pattern most
likely represents a hydroxylated PC (16:0/20:4) and this agrees with previously
published literature37. Therefore, marker with m/z 798.6 was predicted to be hydroxylated PC
(36:4) +H+.

Due to the presence of a fragment ion at m/z 184.07 and a peak indicating water loss from the
precursor, the marker with m/z 895.7 likely represents an oxidized sphingomyelin (SM) (odd
M+H+ having even neutral mass). Oxidized SM’s have not been commonly studied using mass
spectrometry38. Therefore, the structure for m/z 895.7 could not be predicted with certainty.

Tandem MS studies were also performed on a triacylglycerol standard, TG (16:0/18:1/16:0) that
displayed an ammoniated precursor peak at m/z 850.7. As shown in Figure 3.7, in the
fragmentation spectrum of precursor m/z 850.7 (M+NH4+) a fragment ion at m/z 551.5
corresponding to diacylglycerol (DG) 16:0/16:0+ and a fragment ion at m/z 577.5 corresponding
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Figure 3.7 MS2 spectrum for a triacylglycerol standard TG (16:0/18:1/16:0) having m/z 850.7
(M+NH4+). The fragment ion at m/z 551.5 corresponds to diacylglycerol 16:0/16:0+ resulting from
the neutral loss of 18:1 from the precursor. Similarly, the fragment ion at m/z 577.5 corresponds to
diacylglycerol 16:0/18:1+ resulting from the neutral loss of 16:0 from the precursor ion.
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to diacylglycerol (DG) 16:0/18:1+ were observed. These ions result from the neutral losses of 18:1
and 16:0 from the precursor ion. These fragments were predicted and no other fragments due to
truncations, recombinations, or other transformations were observed. Based on MS2 fragmentation
results, the markers having m/z values of 916.8, 920.7, 928.8, 954.8, 956.8 and 958.8 represented
triacylglycerols. MS2 spectrum of the marker m/z 916.8 (Fig 3.8) displayed a fragment at m/z
881.7 likely to be due to neutral loss of water and ammonia. This suggested that m/z 916.8 is an
ammoniated adduct (M+NH4+) of an oxidized triacylglycerol. The peak was predicted to be
epoxide of OOOep based on published studies of such compounds and identified by the presence
of oxidized DAG fragments39-40. For our biomarker, a fragment at m/z 617.5 corresponding
possibly to epoxy diacylglycerol of OOep+39 and a fragment at m/z 603.5 corresponding possibly
to OO+ 41 were observed in the MS2.
Fragmentation studies of marker m/z 920.8 resulted in the production of fragment ions at m/z 575.5,
623.5 and 647.5 corresponding quite possibly to DAG fragments of 16:0/18:2+, 16:0/22:6+ and
18:2/22:6. Therefore, it is predicted to be a TG (16:0/18:2/22:6+) +NH4+. Fragmentation spectrum
of the marker with m/z 928.8 displayed fragment ions at m/z 601.5, 613.5, 629.5 and 631.5
consistent with the fragmentation pattern of ammoniated adduct (M+ NH4+) of LLL-monohydroperoxide42.

MS2 studies of lipids with m/z 954.8, 956.8 and m/z 958.8 resulted in water losses from their
ammoniated (M+NH4+) precursor ions suggesting oxidized lipids. Some other abundant fragment
ion peaks represented neutral loss of fatty acids from TAG species indicating that markers with
m/z 954.8, 956.8 and 958.8 belong to the class of TAG lipids.

114

Figure 3.8 MS2 spectrum for a lipid marker with m/z 916.8. It was predicted to be an ammoniated
adduct of OOOep. The fragment ions at m/z 617.5 and m/z 603.5 are likely to be OOep+ and OO+.
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Unambiguous identification could not be made for these TAG’s because of their complicated
spectra which may have contained a second overlapping isobaric or near isobaric species.
The markers with m/z 425 and m/z 462 are very likely lipids but with unknown identities due to
fragmentation patterns without precedence in the literature or any of the databases.

3.5 Discussion
These studies tested the hypothesis that measurement of serum lipid biomarkers early in pregnancy
would identify patients at risk for developing preeclampsia later in that pregnancy. Using a
‘global’ or in-depth or ‘shotgun’ serum lipidomics approach, these studies suggest that there are
predictive preeclampsia biomarkers.

Global serum lipidomic approaches are relatively new and have been applied to only a few
clinical indications, e.g. Alzheimer’s disease43-44. To our knowledge they have not been previously
applied to preeclampsia, although there have been a few reports of altered cholesterol and
triglyceride profiles in preeclampsia45-47.

Interest in lipids has increased as it has been recognized that lipids are more widely
involved in cell regulatory pathways than previously thought. Lipids then may not only be altered
in response to disease but it is possible that some circulating or cellular lipid species may mediate
or contribute to aspects of disease. Given the uncertainties in the etiology and prediction of
preeclampsia, there is interest in both developing better assessments of preeclampsia risk as well
as better understanding the early changes that precede the fully manifest disorder.
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Our approach led to the detection and confirmation of 23 unique lipid biomarkers for
preeclampsia. It is entirely possible that these circulating factors reflect the consequence of early
disease, but some may have a more direct biological role. In the absence of an accepted animal
model for preeclampsia, early events leading to this disease are poorly understood. A number of
lipidomic biomarkers based on their lipid class and other potential characterization could be related
to pathological processes linked to preeclampsia. Thus, considering the changes in these specific
biomarkers may be useful in providing biochemical information about early antecedents of this
disease. Based on previous literature, some are at least suggestive. For example, among the several
markers, the peak at m/z 383.3, was predicted to be an oxidized cholesterol (keto or epoxy). 7ketocholesterol, which has the same mass, has been proposed to contribute to atherosclerosis48
and vascular changes similar to atherosclerotic disease have been reported in preeclampsia49. This
might explain the higher levels of this marker observed in women with later preeclampsia.
The candidate biomarkers having m/z values 734, 760, 784, 796, 810 and 836 were found to be
higher in the serum of preeclamptic women and belong to the lipid class of
glycerophosphocholines (PC). Placental ischemia and apoptosis have been reported in
preeclampsia, resulting in cell lysis with release of membrane constituents, including likely
phosphatidylcholines, into the circulation50-51. This might explain the higher levels of these
markers in preeclamptic cases.

The marker with m/z 798 was predicted to be an oxidized (hydroxylated) PC (16:0/20:4)
as indicated by the fragmentation pattern seen and consistent with other studies 37. The exposure
of PC species to reactive oxygen species (ROS) can result in oxidation of the species. There have
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been several reports of increased production of ROS in preeclampsia, which might explain the
increased production of this marker in preeclamptic cases52.

Currently, there are no accepted biomarkers for predicting preeclampsia. A number of
candidates have been proposed, especially pro-angiogenic and anti-angiogenic factors, and while
they have repeatedly demonstrated changes in many women with established disease, they have
shown poor sensitivity and specificity in predicting all forms of preeclampsia11-13. Therefore, there
continues to be a need for predictive biomarkers of this disorder with more reliable sensitivities
and specificities. The AUC values of 0.89 for two panels of markers detected in our study are
substantially better than the previously reported values in the literature. The utility of these markers
across two studies suggests these they should be considered of interest, especially given their being
found early in the pregnancy and predicting events months later.

Utilitzation of this direct lipidomic approach as used here could provide a high throughput method
for analysis of individual lipid species from diverse classes without a chromatographic separation
step. This method provides comparative quantitation of species and with standards could allow
for absolute quantitation. MS methods are currently in use in the clinical laboratory, e.g. drugs of
abuse analysis. In addition, our approach allows for chemical characterization of interesting lipids
as well as analysis analogous to multiple reaction monitoring as used for peptides and proteins.
This method can have a linear range above 1000, even over the low concentration range, making
it efficient for studying low abundant lipid species53.
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The approach analyzed ~2,000 lipids but could also be carried out in the negative ion mode
providing an even more comprehensive evaluation of serum lipids were it needed. This expansion
of scope would likely provide additional useful lipid biomarkers for early diagnosis of
preeclampsia. The current approach represents a versatile method requiring relatively simple
specimen preparation and demonstrating adequate reproducibility. As such, it could be applied to
the analysis of blood samples for potentially many other clinical targets.

While the current studies are suggestive, the specimens available were primarily from
Caucasian subjects. It is recognized that additional studies are needed to determine whether the
markers found are more universal in their application. Certainly, more serum lipidomic studies
are needed to demonstrate clinical utility. Nevertheless, global serum lipidomics is a valuable and
robust approach for the discovery and identification of lipid biomarkers for disease and may have
provided useful predictive markers for preeclampsia.
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Chapter 4
Discovery and Confirmation of Diagnostic Serum Lipid Biomarkers for
Alzheimer’s Disease using Direct Infusion Mass spectrometry
4.1 Abstract
Alzheimers disease (AD) is a neurodegenerative disorder lacking early diagnosis and treatment.
Lipids have been implicated as key regulators in a number of neurodegenerative disorders
including Alzheimer’s disease. A shotgun lipidomic approach was undertaken to determine if lipid
biomarkers exist that can discriminate AD cases (all stages) from controls. The discovery study
involved sera from 29 different stage AD cases and 32 controls. Lipid extraction was performed
using organic solvent and the samples were directly infused into a time-of-flight mass
spectrometer. Statistically significant lipid markers demonstrating differences between AD cases
and controls were detected. These potential lipid markers were reevaluated in a second
confirmatory study involving 27 cases and 30 controls. The initial study detected 89 potential AD
markers. Of these, 35 markers continued to be statistically significant in the second confirmatory
set. Tandem MS studies were performed and almost all of the confirmed markers were identified.
Using the confirmed markers, several multi-marker panels with AUC > 0.87 were developed for
any stage AD cases vs controls. Additionally, using confirmed biomarkers, models were developed
for individual stages of AD. Multi-marker panels with AUCs > 0.90 were developed for each
specific CDR vs controls, including the earliest stage of AD. These lipidomic biomarkers are likely
to distinguish AD cases regardless of the stage from controls.

125

4.2 Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause
of age-related dementia1-2. Currently, as many as 25 million people may have AD with more than
4 million new cases reported every year3. AD is characterized by declining cognitive function
including memory, language, motor control, spatial ability and executive function and in many
individuals an eventual marked change in behavior. General risk factors for AD include age,
female sex and certain genetic backdrops. However, the actual risk of an individual for AD cannot
be determined currently. This in turn has limited drug trials.

Several hypotheses exist for AD etiology. The most common theory proposes that increased
amyloid β peptide (Aβ) deposits, resulting from the cleavage of amyloid precursor protein by βsecretase and γ-secretase, lead to amyloid plaque formation4. Another hypothesis proposes the
formation of neurofibrillary tangles of (NFT) of abnormally phosphorylated tau protein5. These
are proposed to be the primary pathological events leading to loss of synapses and neurons
producing the clinical sequelae.

Mild cognitive impairment (MCI) is often a precursor of AD but may be linked to other types of
dementia. The definite diagnosis of AD can only be made by postmortem histopathological
analysis. Currently, the clinical diagnosis of AD is still subjective and based on medical records,
lab tests, neuroimaging and neuropsychological evaluation. Early diagnosis is challenging,
although clinical centers specializing in AD appear better able to predict which subjects with MCI
will progress to AD, but generally accuracies vary from 20-100%6.
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More quantitative methods of AD diagnosis exist but are not routinely used. A wide variety of
imaging techniques has been used in the past for AD diagnosis. Magnetic resonance imaging
(MRI) measuring hippocampal volume as a measure of neuron loss has been widely reviewed in
literature7. Positron emission tomography (PET) using ligands such as Pittsburgh compound B
(11C-PIB) that bind Aβ plaques8-9 have also been extensively studied. A novel ligand (S)[18F]THK5117 that binds to tau aggregates has also been explored recently10. Fluoro-deoxyglucose
positron emission tomography (FDG-PET) has been used in past studies involving mild AD
patients that measures reduced glucose metabolism due to synaptic loss in brain11. These
techniques are often sensitive but are not broadly used, due to their being very expensive, and
hence are more often employed for clinical research12. Studies of cerebrospinal fluid Aβ and
phosphorylated tau have found them to be reasonably accurate for mid to late stage AD but of
limited use in early or very early stage AD6. Blood levels of tau protein are below the detection
limit for many assays13. Serum or plasma Aβ peptide measured revealed poor diagnostic value for
AD in a number of studies14-15. Also, some studies indicated that there is no correlation between
Aβ peptide and the severity of dementia16. While there is an increase in AD risk when an individual
has the apolipoprotein E ε4 (ApoE4) allele or alleles, yet, it likewise cannot be used as an AD
biomarker because of its low predictive value17.

Currently then, there are as yet no accepted serologic or radiologic tests to diagnose AD, most
especially early stage AD. Imaging using radio-ligands is promising and shows good results for
many with AD but it is expensive, time consuming and invasive. Consequently, there is an unmet
need to find serum biomarkers for AD, especially for very early disease. Moreover, other
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assessments such future risk of AD, rates of AD progression, responsiveness to therapies may yet
be possible with as yet undiscovered serum biomarkers.

Lipids are increasingly recognized as participants in disease, frequently modified in consequence
of disease but also occasionally as mediators of disease18. In AD, neurodegeneration, a key feature
of AD, leads to breakdown of cell membrane, resulting in abnormal metabolism of membrane
lipids19. Also, there is a strong evidence of oxidative stress in brains of AD patients 20-21. There are
reports that continuous oxidative stress led to accumulation of oxidized lipid species namely,
isoprostanes22 or malinoaldehyde23. Some studies have demonstrated alterations in ceramides with
different stages of AD24-26. A recent study indicated breakdown of phosphatidylcholine species
was an indicator of neurodegeneration19.

Therefore, it is reasonable that global characterization of alterations in the serum lipidome between
AD cases and controls would likely identify biomarkers for diagnosis of AD, perhaps even early
AD. The research reported here tested this hypothesis by applying an untargeted, label free, global
lipidomic approach that employs direct electrospray ionization, time-of-flight mass spectrometry
(ESI-TOFMS) to serum from AD patients and controls. Diagnostically useful AD lipid biomarker
panels were sought and the results suggest that such lipid biomarkers exist and represent
biologically relevant changes in consequence of AD.

4.3 Methods
4.3.1 Study Population
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The serum specimens were obtained from the Knight Alzheimer’s Disease Research Center
(knight ADRC) at the Washington University School of Medicine, St. Louis, MO. The study was
approved by Institutional Review Boards (IRB) at both the Knight ADRC and Brigham Young
University (BYU) for specimen analysis.

In an initial discovery set, sera from 29 cases and 32 controls were analyzed. AD cases included
patients having different stages of AD as indicated by differing clinical dementia ratings (CDR).
Cases included 10 subjects with mild cognitive impairment (MCI) or very mild AD (CDR 0.5), 10
with mild AD (CDR 1) and 9 with moderate AD (CDR 2). The confirmatory set included 27 cases
and 30 controls. AD cases included 9 patients with CDR 0.5, 9 with CDR 1and 9 with CDR 2.
The demographics for the patients whose samples were used for the discovery and confirmatory
set are summarized in Tables 4.1 and 4.2. Cases and controls excluded patients with co-morbidities
including thyroid disease, diabetes, etc. Blood specimens after collection, were allowed to clot at
room temperature for 30 min followed by separation of serum, removal of aliquots with immediate
freezing. Serum specimens were maintained frozen at < -800C until used in these studies.

4.3.2 Sample Preparation
Lipid extraction from serum was accomplished using a modified published method (31). To 200
µL of serum, 1.8 mL of a mixture of hexane and isopropanol (3:2, v: v) and 300 µL of 0.5 M
KH2PO4 were added to a glass tube followed by vigorous vortexing. The stoppered tubes were
further mixed on a motorize shaker at room temperature for 1 hr at 80 rpm. To enhance phase
separation, 150 µL of water was added and the samples were then centrifuged at 2000 rpm for 12
min.
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Table 4.1 AD demographics for the first discovery set of samples
No.
CASES

29

18/29 F, 11/29 M

Age (mean)

Apo E status

79.7 ± 6.6

Allele 4 positive - 20
Allele 4 negative - 9

CONTROLS

32

18/32 F, 14/32 M

78.1 ± 6.3

Allele 4 positive - 7
Allele 4 negative - 25
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Table 4.2 AD demographics for the second confirmatory set of samples
No.
CASES

27

16/27 F, 11/27 M

Age (mean)

Apo E status

79.6 ± 8.5

Allele 4 positive - 14
Allele 4 negative - 13

CONTROLS

30

12/30 F, 18/30 M

77.2 ± 6.2

Allele 4 positive - 12
Allele 4 negative - 18
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The upper organic phase containing the lipids was collected and dried under nitrogen.
Dried lipid samples were redissolved in 200 µL of chloroform: methanol (3:1) and stored at -80
0

C until MS analysis.

4.3.3 Mass Spectrometric Analysis of the Lipid Extract
To a 20 µL aliquot of the sample extract, 23 µL of chloroform, 46 µL of methanol and 14 µL of
12 µM ammonium acetate were added and mixed. The samples were directly injected into the mass
spectrometer (6530 LC/MS ESI-QTOF Agilent Technologies) through an electrospray ionization
(ESI) source operated in the positive ion mode. A syringe pump was utilized to inject samples at
the flow rate of 10µL/min for 4 min. The ESI source used a standard spray needle having an i.d.
of 120 µm. The capillary voltage was set at 3500 V. MS data was collected from mass to charge
ratios (m/z) of 100-3000 with an acquisition rate of 1 spectrum/sec. The nebulizer gas and drying
gas parameters were optimized to obtain a stable flow. The drying gas was set to 5 L/min at 3250C
with a nebulization gas pressure of 1.03 bar. Agilent Mass Hunter-Qualitative software was used
for data analysis. Each specimen generated a mass spectrum from m/z 100 to 3000 from the total
ion chromatogram (TIC the sum of all ion counts). A peak list having m/z values for all peaks with
their abundances was generated from the mass spectrum.

To reduce analytical variability all MS peaks were normalized. For normalization, 7 abundant
peaks representing different classes of lipids were chosen as a reference set. The sum of the
intensities of these 7 peaks was used for normalizing all the peaks across the mass spectrum.
For the second confirmatory study, all the samples were processed and directly infused into the
instrument using the same method at a flow rate of 10 µL/min for 5 min, the change being due to
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a somewhat larger diameter spray needle, employed to reduce blockage of the ESI needle. All
other parameters were kept identical. All the candidate markers significant in the initial, discovery
set were reanalyzed for their performance in the second confirmation set.

4.3.4 Chemical Characterization of the Replicating Lipid Biomarkers by Tandem MS
Tandem MS studies were performed on all 35 replicating lipid AD biomarkers. Fragmentation
was accomplished using collision-induced dissociation (CID) on an ESI-quadrupole-TOFMS.
Both a QSTAR Pulsar 1 quadrupole and an Agilent 6530 Q-TOF MS were employed using the
positive ion mode.

For the QSTAR, the capillary voltage set to 4200 V. Samples were injected directly at a flow rate
of 2 µL/min and a specific precursor ion targeted in the quadrupole. A spectral acquisition rate of
1 spectrum/sec was used. Focusing and declustering potentials were set to 290 V and 65 V. CID
was performed using nitrogen or argon gas. In order to obtain more complete fragmentation
coverage, multiple fragmentation energies were used. MS/MS spectra were collected for 2 min.
The (multi-channel analyzer function was used to sum all 120 MS/MS spectra and this resulted in
higher signal to noise.

For the Agilent 6530, samples were injected at the flow rate of 10 µL/min with the capillary voltage
set to 3500 V. The drying gas flow rate and the temperature were 5 L/min and 300 0C. MS/MS
spectra were collected from m/z 50-3000 at a rate was 1 spectrum /sec. Collision energies were
optimized to obtain maximum fragmentation coverage. Individual scans were summed using the
add feature of the Mass Hunter program to improve the signal to noise. The targeted MS/MS mode
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was used to select and fragment the parent ion of interest. The resolution was set to narrow with
1.3 m/z range.
Exact mass studies were accomplished by reference to a set of internal standards added to
specimen. Lipidmaps.org was used to tentatively determine all the possible lipid species from
different classes for a particular parent peak. Furthermore, product ions, neutral fragment losses,
fragmentation patterns and exact masses of parent and daughter ions were evaluated and where
possible compared with experimentally observed fragmentation patterns or with in silico predicted
fragmentations to clarify and confirm the classes and composition of the markers.

4.3.5 Statistical Analyses
The normalized intensities of all monoisotopic peaks (abundance>150) were subjected to a twotailed Student’s t-test. Peaks having a p-value < 0.05 in the first study were considered for further
evaluation in a second, independent study. The markers that continued to show p-values < 0.05 in
the second confirmatory set were considered candidates and used for biomarker panel
development. In addition to peaks having p-values <0.05 being considered, species with p-values
< 0.10 were also considered for multi-marker modeling recognizing that they might identify more
specifically subgroups of patients within the broader diagnosis and hence be complementary.
Models were developed to improve diagnostic performance, using a series of forward stepwise
variable selection procedures based on the AUC (corrected for optimism using the traditional
bootstrap27) or overall error rate (based on leave-one-out cross validation or the optimismcorrected .632+ bootstrap method28) were performed. To find the combination of variables
resulting in the best discriminatory ability, variable addition ended when the inclusion of any other
variables did not result in improved performance. Furthermore, with the goal of identifying the
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most parsimonious models, the forward stepwise variable selection procedure was sometimes
constrained to stop after the inclusion of 3 or 4 variables. Models were then compared (in terms of
estimated AUC, corrected AUC, and corrected error rate). Due to the binary nature of the data
(presence or absence of Alzheimer's disease), all models employed logistic regression.

4.4 Results
The question addressed by this work was whether one or more serum lipids could identify patients
with AD. A ‘global’ serum lipidomics approach was used to determine if lipid biomarkers exist
that identifies patients clinically diagnosed with AD, including those with early stage AD. The
approach was used in two separate studies and the answer appears to be yes.

4.4.1 Discovery of candidate serum lipid AD diagnostic biomarkers
The first study of 29 cases and 32 controls was used to discover potential biomarkers for any stage
AD. The approach yielded 89 lipids of interest as part of this discovery set. These are summarized
in Table 4.3.

4.4.2 Confirmation of candidate AD biomarkers from the first study
A second confirmatory study was conducted to evaluate the performance of the 89 previously
discovered lipid markers in a new set of samples. This new study involved serum from 27 AD
cases and 30 controls. Of the 89 markers, 35 continued to show statistically significant or near
significant p-values. These diagnostic candidates are listed in Table 4.4.
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Table 4.3 Candidate PE lipid biomarkers
No.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.

m/z
228.2
229.1
243.2
281.1
282.2
280.9
295.1
371.35
387.17
391.17
415.2
430.3
432.2
437.1
447.3
453.1
463.3
488.3
496.3
514.4
520.3
522.3
524.3
577.5
579.5
601.5
602.4
603.5
610.5
611.3
614.5
616.4
620.4
627.4
630.5
639.4
640.6
642.6
654.3
664.6
666.9

P value
0.06
0.1
0.004
2.6X10-5
8.8x10-5
0.04
6.7X10-5
0.001
0.04
0.009
2.3X10-5
0.03
2.6X 10-5
0.01
2.2X10-10
0.07
0.02
0.004
1.1X 10-6
0.01
0.0004
5.4X10-6
2.7X10-5
0.008
0.001
0.04
0.02
0.01
0.05
0.1
0.07
0.08
0.004
0.07
0.03
0.03
0.0001
5.3X10-9
7.4X10-7
0.1
0.01
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Higher in
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Cases
Controls
Controls
Cases
Controls
Controls
Cases
Cases
Cases
Controls
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Controls
Controls
Controls
Cases
Cases
Cases
Controls
Controls
Controls
Controls
Controls

42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.

669.6
671.6
688.6
701.5
703.5
714.6
717.5
724.5
727.5
729.6
731.6
742.6
744.6
750.5
752.5
754.5
759.1
760.8
760.9
761.1
766.6
768.6
778.5
786.6
792.6
794.6
799.6
810.8
812.6
820.7
822.7
824.6
842.6
844.7
846.7
848.7
850.7
860.7
862.7
864.6
881.7
886.7
888.8
890.8
907.8

4.4X10-6
0.005
0.01
0.008
0.02
0.07
0.06
0.0007
2.3X10-10
3.6X10-8
0.04
0.07
0.04
4X10-5
0.001
0.03
0.007
0.09
0.08
0.08
0.02
0.0008
0.005
0.02
0.005
0.02
0.1
0.02
0.07
0.07
0.03
0.02
0.02
0.06
0.01
0.02
0.03
0.01
0.007
0.003
0.0005
0.02
0.01
0.01
0.009
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Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Cases
Cases
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Controls
Cases
Cases
Cases
Cases
Controls
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases

87.
88.
89.

912.7
915.8
930.8

0.005
2.3X10-5
0.01
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Cases
Cases
Cases

Table 4.4 Potential markers continued to be statistically significant in the second confirmatory set
S. No

Exact mass

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.

229.14
430.38
488.39
496.33
514.38
522.35
577.51
601.52
603.53
602.44
610.53
620.42
630.47
703.56
714.62
724.52
778.54
766.57
799.66
820.73
822.75
824.62
842.61
846.75
848.77
850.78
862.78
860.77
864.61
881.74
886.78
888.80
890.81
912.76
930.84

P value in first discovery P value in confirmatory
set

0.1
0.03
0.004
10-5
0.01
10-6
0.008
0.04
0.02
0.02
0.05
0.004
0.03
0.02
0.07
0.0007
0.005
0.02
0.1
0.07
0.03
0.02
0.02
0.01
0.02
0.03
0.007
0.01
0.001
0.0005
0.02
0.01
0.005
0.005
0.01

set
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0.003
0.001
0.09
0.06
0.01
0.02
0.009
0.02
0.003
0.006
0.001
0.0003
0.007
0.1
0.002
0.04
0.09
0.07
0.05
0.02
0.01
0.01
0.007
0.002
0.004
0.01
0.007
0.006
0.08
0.1
0.01
0.008
0.003
0.05
0.01

Higher in
Controls
Cases
Controls
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Controls
Cases
Controls
Controls
Controls
Controls
Controls
Controls
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases
Cases

4.4.3 Chemical characterization of the validated AD diagnostic lipid biomarkers
Tandem MS studies were performed on all the 35 confirmed lipid biomarkers to chemically
characterize them. The exact mass, elemental composition, lipid class and molecular components
were successfully determined for most of the confirmed lipid biomarkers. The assigned class and
identified features of these markers are provided in Table 4.5. The rationale for the structural
chemical assignments of the validated markers are also explained in Table 4.5.

Our fragmentation studies on biomarker m/z 430.4 produced fragments at m/z 165 and m/z 205
consistent with the published fragmentation pattern of vitamin E29.

Based additionally on

additional peaks in the broader fragmentation spectrum and on its putative elemental composition
(C29H50O2+) as determined by exact mass studies, this lipid with m/z 430.4 was completely
coinsistent with its being vitamin E29.

Fragmentation spectra of the markers with m/z 496.3 and 522.3 displayed a prominent peak at m/z
184.07 corresponding to a phosphocholine moiety. Fragmentation patterns indicating neutral
losses from the parent precursor ion suggest fatty acids present in the molecule. The fatty acid
constituents were determined by comparing the theoretically produced fragments generated by the
Lipid MS predictor feature of Lipid Maps with the experimentally produced fragments from
biomarker.
Elemental compositions were also predicted by exact mass studies. These peaks were classified
as lysophosphatidylcholines (LPC). The markers with m/z 496.3 and m/z 522.3 were most likely
to be LPC-16:0 and LPC-18:1, consistent with the previously published literature30.
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The elemental composition of marker m/z 577.5 was predicted to be C37H69O4+. This species could
arise from the neutral loss of the head group from a parent phospholipid (i.e. M+H+- head group),
most likely a glycerophosphoserine, glycerophosphoethanolamine or glycerophosphoglycerol, and
represent the remaining two fatty acids attached to the glycerol backbone. However, it could also
arise from the neutral loss of a fatty acid from a triacylglycerol 31. We also observed the product
ion peaks at m/z 265 and m/z 239. In the published literature, these were shown to be acylium ions
(RCO+) for 18:1 and 16:0 fatty acid substituents31.

Similarly, the elemental compositions of markers m/z 601.5 and m/z 603.5 were proposed to be
C39H69O4+ and C39H71O4+. These are also predicted to arise from the neutral loss of the head group
from

a

glycerophosphoserine,

glycerophosphoethanolamine,

glycerophosphoglycerol,

glycerophosphatidylcholine or through the neutral loss of a fatty acid from a triacylglycerol and
appears to represent the remaining two fatty acids attached to a glycerol backbone. Based on the
published literature, the acylium ions we observed in the MS2 spectrum of the precursor ion m/z
601.5 were consistent with 18:1 (m/z 265) and 18:2 (m/z 263)31. Likewise, the fragmentation
spectrum of the marker with m/z 603.5 presented peaks consistent with acylium ions from 18:1
(m/z 265) and 18:1 (m/z 265) fatty acids31.

The markers with m/z 229.1, 602.4, 610.5, 620.4 and 630.4 were very likely lipids but with
fragments and fragment patterns not previously described. Their predicted elemental compositions
based on exact mass studies are summarized in Table 4.5.
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A dominant peak at m/z 184.06 was also displayed in the MS2 spectra of markers with m/z 703.5
and 799.6 indicating phosphocholine containing species. Therefore, the fragmentation spectra of
the markers with m/z 703.5 and m/z 799.5 were most consistent with and were predicted to be
sphingomyelins (SM) (SM (d18:1/16:0) or SM (d16:1/18:0))

32

and (SM (d18:2/23:0) or SM

(d17:1/24:1)) .

Fragmentation studies applied to the marker m/z 714.6 resulted in a product fragment ion m/z
369.4. This same fragment has been shown to be characteristic of cholesterol esters in the studies
of others33. The fragmentation results were consistent with and suggest it to be a cholesterol ester
of docosahexaenoic acid (22:6)34.

The markers with m/z 724.5 and m/z 778.5 were likely glycerophosphoethanolamines (GPETn) as
indicated by neutral loss of 141 from the parent ion with fragmentation. MS/MS spectra of m/z
724.5 displayed product ions at m/z 364 and m/z 361 consistent with previous studies as being a
16:0p fatty acid group at the sn-1 position and a 20:4 fatty acid at sn-2 position35. Its putative
identification (16:0p/20:4) GPETn was also consistent with its elemental composition of
C41H74NO7P+H+. Similarly, the fragmentation of the marker m/z 778.5 produced product ions at
m/z 392 and m/z 387 potentially, indicating the presence of an 18:0p fatty acyl group at sn-1
position and a 22:5 acyl group at sn-2 position as observed in the previously published literature35.
Based on prior studies, m/z 778.5 was predicted to be (18:0p/22:5) GPETn with an elemental
composition of C45H80NO7P +H+.
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A product ion at m/z 184.06 was also observed in the fragmentation spectra of markers with m/z
766.6, and 842.6 indicating they are glycerophosphocholines. Based on the fragmentation pattern,
Lipid Maps and exact mass studies, our results were most consistent with the m/z 766.6 being PC
(O-16:1/20:4).

The marker with m/z 842.6 displayed fragment ions at m/z 808.6 and m/z 824.6 corresponding to
loss of hydrogen peroxide (H2O2) and water consistent with previous published literature36. An
additional fragment ion at m/z 524.3 indicating presence of a C18:0 fatty acid was also observed.
Therefore the marker m/z 842.6 is predicted to be a protonated oxidized PC having a
hydroperoxide group attached to PC (18:0/20:4).

The markers with m/z 824.6 and m/z 864.6 had an overlapping peak adjacent to them. These could
not be specifically isolated by the instrument and the fragmentation spectrum involved fragments
from the overlapping peaks as well. Although their fragmentation spectrum displayed a product
ion at m/z 184.06 indicating a phosphocholine group, peak classification can’t be made as the peak
might represent a fragment ion of the overlapping peak. This problem could be solved with an
instrument with a high resolving power such as Orbitrap Elite (Thermo scientific).

A number of peaks, i.e. those with m/z 488.3, 820.7, 822.7, 846.7, 848.7, 850.7, 860.7, 862.7,
886.7, 888.8, 890.8, 912.7 and 930.8 were likely to be ammoniated adducts of triacyglycerols
(TAGs). A product ion representing the neutral loss of 17 was found for each and represents
ammonia loss, which is consistent with the TAGs readily forming ammonium adducts, that is the
precursor ion was ammoniated (M+NH4+) and ammonia was lost upon collision37. The species
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with m/z 881.7 was found to be the protonated form (M+H+) of a TAG. The combinations of fatty
acids were predicted by observing the neutral loss of acylium ions from the precursor ion but
absolute assignment is not possible in the absence of standards.

The predicted fatty acid

components for all the TAG’s are provided in Table 4.5.

The species with m/z 912.8 displayed fragment ions at m/z 599.5, m/z 601.6 and m/z 615.5
corresponding to diacylglycerol fragments of (18:2/18:2)+, (18:2/18:1)+ and (18:1/18:2epoxide)+.
Therefore, marker m/z 912.8 was predicted to be an epoxide of 18:1/18:2/18:2 (OLLep)+NH4+
consistent with the previously published literature 38.
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Table 4.5 Chemical characterization of the lipid biomarkers
No

m/z

Exact
mass

1.

229.1 229.14

2.

430.4 430.38

3.

Adduct

Elemental
composition

Class

Possible identity

C12H21O4+
M+

C29H50O2+

Sterols

Vitamin e

488.4 488.39 M+NH4+ C27H50O6+NH4+

Triacylglycerols

TG-8:0/8:0/8:0

4.

496.3 496.33 M+H+

Lysophosphocholines

LysoPC 16:0

5.

514.4 514.38

6.

522.3 522.35 M+H+

C26H52NO7P+H+

7.

577.5 577.51

M+

C37H69O4+

8.

601.5 601.52

M+

C39H69O4+

9.

603.5 603.53

M+

C39H71O4+

C24H50NO7P+H+

---

10. 602.4 602.44

C44H58O+

11. 610.5 610.53

C41H70O3+

12. 620.4 620.42

C43H56O3+
C47H56

13. 630.4 630.47

C46H62O+

14. 703.5 703.56 M+H+

C43H76N2O6 +H+

Lysophosphocholines

LysoPC 18:1

Sphingomyelins

SM(d18:1/16:0)
SM(d16:1/18:0)

or
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or

15. 714.6 714.61 M+NH4+ C49H76O2+NH4+

Cholesterol esters

C22:6
ester

16. 724.5 724.52 M+H+

Glycerophosphatidyleth-

PE(16:0p/ 20:4)

C41H74NO7P +H+

cholesterol

anolamines
17. 778.5 778.57 M+H+

C45H80NO7P +H

Glycerophosphatidyleth-

PE(18:0p/ 22:5)

anolamines
18. 766.6 766.57 M+H+

C44H80NO7P +H+

19. 799.6 799.66 M+H+

C46H91N2O6P
+H+

Glycerophosphocholines

PC(O-16:1/20:4)

Sphingomyelins

SM(d17:1/24:1)
SM(d18:2/23:0)

or

20. 820.7 820.73 M+NH4+ C51H94O6+NH4+

Triacylglycerols

TG-16:0/16:1/16:1

21. 822.7 822.75 M+NH4+ C51H96O6+NH4+

Triacylglycerols

TG-16:0/16:0/16:1

22. 824.6 824.61 M+H+

23. 842.6 842.61 M+H+

C46H84NO10P
+H+

Glycerophosphocholines

PC(18:0/20:4)+OO
H +H+

24. 846.7 846.75 M+NH4+ C53H96O6 +NH4+

Triacylglycerol

TG-16:0/16:1/18:2

25. 848.7 848.77 M+NH4+ C53H98O6 +NH4+

Triacylglycerol

TG-16:0/16:1/18:1

26. 850.7 850.78 M+NH4+ C53H100O6 +NH4+ Triacylglycerol

TG16:0/16:0/18:1

27. 862.7 862.78 M+NH4+ C54H100O6 +NH4+

Triacylglycerol

TG16:0/17:0/18:2

28. 860.7 860.77 M+NH4+ C54H98O6 +NH4+

Triacylglycerol

TG16:1/17:1/18:1

29. 864.6 864.61 M+H+
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30. 881.7 881.74 M+H+

C56H100O6 + H+

Triacylglycerol

TG-16:0/18:0/20:5

31. 886.7 886.78 M+NH4+ C56H100O6 +NH4+

Triacylglycerol

TG-17:0/18:1/18:3

32. 888.8 888.80 M+NH4+ C56H102O6 +NH4+

Triacylglycerol

TG-17:0/18:1/18:2

33. 890.8 890.81 M+NH4+ C56H104O6 +NH4+

Triacylglycerol

TG-17:0/18:0/18:2

34. 912.7 912.76 M+NH4+ C57H98O7 +NH4+

Oxidized

18:1/18:2/18:2

triacylglycerols

epoxide

Triacylglycerol

TG-18:1/18:2/20:0

35. 930.8 930.84 M+NH4+ C59H108O6 +NH4+
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4.4.4 Modeling of Multi Marker Panels Diagnostic of AD
Statistical modeling was performed on the 35 validated markers to develop multi-marker panels
with higher predictive values. Several panels using combinations of 4-6 markers were found to
have AUCs > 0.87 as summarized in Table 4.6. The ROC curves for one of the best multi-marker
combinations [AUCs of 0.90 (sensitivity > 85% and specificity > 80%)] are shown in Figure 4.1.

Likewise, multi-marker panels were also developed for individual stages of AD (CDR 0.5, 1 or 2)
versus controls. Several panels formed from combinations of 3-5 markers had AUC values > 0.94
and are listed in Table 4.7. The ROC curves for the three best multi-marker combinations for each
individual AD stage (CDR 0.5, 1 and 2) all having AUCs >0.93 and sensitivities >90% at
specificities of at least 84% are shown in Fig 4.2, 4.3 and 4.4.

4.5 Discussion
The early diagnosis of AD remains challenging. With newer ligand imaging methods, earlier
diagnosis appears possible for many patients with AD; however, the approach is expensive,
invasive and involved and doesn’t lend itself to routine screening or assessment. Still, many who
investigate this disease believe that neurodegeneration in AD begins long before the appearance
of clinical symptoms. These early changes then would involve molecular changes. As such, there
is a reasonable presumption that very early AD can be identified and that it may be possible
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Table 4.6 Multi-marker panels for any stage AD vs controls having an AUC > 0.87
AUC
0.90
0.90
0.88
0.87

Potential marker combinations
496.3, 714.6, 778.5, 864.6, 488.3, 602.3
522.3, 778.5, 864.6, 488.3, 610.5
864.6, 714.6, 620.4, 778.5
778.5, 864.6, 610.5, 488.3
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ROC curve for m/z 522.3, 778.5,
864.6, 488.3, 610.5

Figure 4.1 Best modeled diagnostic serum biomarker set for AD.
This receiver operator characteristic curve (ROC), generated by logistic regression analysis,
included 5 lipid biomarkers having mass to charge ratios of 522.3, 778.5, 864.6, 488.3 and 610.5.
The AUC was 0.90 with a sensitivity of ~87% at a specificity of ~82%.

150

Table 4.7 Best multi-marker panels for individual stages of AD (CDR 0.5, 1 and 2) vs controls
CDR
0.5
1
2

AUC
0.95
0.93
0.94

Marker combinations in optimized set
620.4, 602.4, 778.5
864.6, 714.6, 778.5, 620.4
620.4, 602.4, 778.5, 488.3
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Figure 4.2 Best modeled diagnostic serum biomarker set for CDR 0.5 vs controls.
This ROC curve was generated by logistic regression analysis on 3 lipid biomarkers having mass to
charge ratios of 620.4, 602.4 and 778.5. The AUC was 0.95 with a sensitivity of ~97% at a specificity
of ~85%.
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Figure 4.3 Best modeled diagnostic serum biomarker set for CDR 1 vs controls.
This ROC curve was generated by logistic regression analysis using 4 lipid biomarkers having mass
to charge ratios of 864.6, 714.6, 778.5 and 620.4. The AUC was 0.93 with a sensitivity of ~97% at a
specificity of ~88%.
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Figure 4.4 Best modeled diagnostic serum biomarker set for CDR 2 vs controls.
This ROC curve was generated using regression analysis of a set of 5 lipid biomarkers having mass
to charge ratios of 864.6, 714.6, 778.5, 842.6 and 620.4. The AUC was 0.94 with a sensitivity of
~98% at a specificity of ~84%.
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to observe and track many of these changes with a simple blood test. Indeed, other recent work
suggests that peptides and lipids are altered early in the disease39.

Lipids are an emerging area of interest in biomedical research40. Indeed, an important role for
lipids in the pathogenesis of AD has been previously considered5. What were once thought of as
largely structural molecules or passive fuel reserves have been more recently shown to reflect
pathology and to participate in disease41.

This is also one of a number of recent studies to employ a global lipidomic approach using direct
infusion mass spectrometry to interrogate serum. Direct infusion mass spectrometry using ESIMS has been shown to be quantitative and faster than other MS analyses and useful in the analysis
of the lipids in the extracts of biological samples42. It allows for the screening of many individual
lipids from diverse lipid classes. This study was conducted to determine if lipid biomarkers existed
that discriminated AD cases from controls, especially patients with very early stage AD and to
address the hypothesis that such markers would provide further insight into AD pathology.

Our approach led to the discovery and confirmation of 35 lipidomic markers differentiating any
stage AD from control across two independent studies. We observed alterations in the levels of
lipid species belonging to various lipid classes, including sterols, sphingomyelins (SM),
glycerophosphocholines (PC), glycerophosphoethanolamines (PE), lysophosphocholines (LPC)
and triacylglycerols (TAG). Combinations of these markers provided panels with ROC curves
having AUCs greater than 0.87 for all stage AD. The best of these provided a sensitivity of 88%
with a specificity of 82% for all stages of AD. The ability of these same markers to identify
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patients with a particular stage of AD versus controls was also modeled. The best models provided
sensitivities of ~97% for CDR 0.5, 1 or 2 individually with specificities of at least 85% for CDR
0.5 and ~87% for CDR 1 or CDR 2. While the number of patients in these subgroups was small,
the results nonetheless suggest strongly that serum lipid biomarkers are present that diagnose AD,
even very early stage AD.

Although a confirmation study was performed, it is well recognized replication of the results from
this study needs to be performed in other large studies across many populations. It would also be
of interest to monitor changes in serum biomarkers over time. Further, given the alterations in
lipids in response to AD, it would be useful to more directly study possible biologic roles for some
of the individual molecular species of lipids in the context of AD.

It was demonstrated that direct infusion mass spectrometry was reasonably effective in a broad,
untargeted analysis of the serum lipidome. It allowed fast, uncomplicated, high throughput and
semi quantitative analysis of >1000 molecular species of lipids. It resulted in reproducible
discrimination of AD cases from controls.

The second goal of the research was to determine whether the observed markers provided insight
into AD pathology. The classification and/or identification of the biomarkers was carried out with
the intent of understanding biochemical changes present in AD, even early AD, asking whether
there was biological plausibility for them.
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One marker with m/z 430.4 was consistent with its being vitamin E. Its levels were found to be
significantly increased in the serum samples of AD cases. This differs from previously reported
results where vitamin E levels were found to be lower in the CSF and plasma of AD patients
44

43-

.

Two markers with m/z 496.3 and m/z 522.3 found to be higher in AD cases belonged to the class
of lysophosphocholines (LPC). Neurodegeneration, a key feature of AD, results in the breakdown
of cell membranes19 potentially increasing the release of membrane molecules into the circulation.
Also, published studies suggest that activation of phospholipase A2 (PLA2), responsible for
hydrolysis of phosphocholines and leading to increased production of lysoPCs, was also increased
in AD patients19. Furthermore, lysoPC produced through hydrolysis of PC by PLA2 can be a
precursor of platelet activating factor (PAF) which in turn acts as a mediator of inflammation45.
There is clear evidence of inflammation in the brains of AD patients 46-47. Alterations in levels of
these markers then might be explained by and potentially represent known pathological events
giving rise to higher levels of lyso-PCs in AD cases. Our results appear consistent with previous
AD findings.

Two markers with m/z 703.5 and m/z 799.6, found to be lower in AD patients, were determined
to be sphingomyelins (SM). This is consistent with a past study which also reported lower SM
levels in AD patients48. SMs are metabolized to ceramides which can play important roles in cell
differentiation, proliferation, and apoptosis49. Ceramides are also known to be involved in
atherosclerosis50. All of these processes have been previously associated with the pathogenesis of
AD51-52.
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Candidate biomarkers with m/z 724.5 and m/z 778.5 were decreased in AD cases. Both belonged
to the class of PEs. Ethanolamine plasmalogen (PlsEtn), representing ~ 90% of all PEs, is highly
enriched in white and grey matter of the human brain. PlsEtn provides a sheath for axons in white
matter and acts as a source of lipid messengers participating in signal transduction in grey matter.
There are several reports of gradual reduction in levels of plasmalogen with increasing severity of
AD53-54. Its deficiency in white matter likely contributes to myelin sheath defects and axonal
dysfunction leading to dementia in AD patients. Plasmalogen deficiency in cerebral grey matter
could result in synapse loss due to membrane instability55 which is another known early event in
AD56. This same process, if somewhat more generalized, might explain the reduced levels of PE
in AD patients in our study.

The candidate marker with m/z 842.6 was identified to be an oxidized PC species elemental an
easily lost OH group. Therefore it’s likely to be PC (18:0/20:4)+OOH +H+ with an elemental
composition of C46H84NO10P+H+. It was found to be higher in AD cases. The increased oxidative

stress observed in neurodegenerative disorders
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likely results in increased lipid oxidation and

would possibly explain the higher levels of this marker among AD cases in our study. Similarly,
the marker with m/z 912.7 was found to be an ammoniated adduct of an oxidized TAG and was
higher in AD cases. AD is associated with increased levels of oxidative stress 58. F2-isoprostane,
produced from polyunsaturated fatty acids as a result of free radical mediated peroxidation has
been reported to be higher in brain and CSF of AD patients. However, its increase in plasma
remains controversial 59.
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Several other candidate lipid markers, those with m/z 820.7, 822.7, 846.7, 848.7, 850.7, 860.7,
862.7, 881.7, 886.7, 888.8, 890.8 and 930.8, all belong to the class of triacylglycerols (TAG) and
were found to be higher in AD cases. There is emerging evidence that elevated triglyceride levels
precede amyloid deposition in AD mouse model60, although the implications of this are unknown.

A previously published untargeted lipidomic and metabolomics approach revealed a blood based
biomarker panel to identify normal individuals who will phenoconvert to MCI or AD within 2-3
years with high accuracy61. The number of subjects who phenocoverted was only 10. Currently,
there are still no US-FDA approved biomarkers for AD diagnosis.
Our study detected novel, previously undescribed potential lipidomic biomarkers for AD. We also
developed panels to predict CDR 0.5,1 and 2 individually. Our work then is complementary to the
above mentioned study and is likely to contribute to improved clinical diagnosis of AD.

Collectively, the results of these studies suggest that useful serum lipid biomarkers allow for the
accurate diagnosis of most patients with AD, regardless of stage. Moreover, the majority of these
biomarkers were found to be relevant lipid species whose altered expression is consistent with
known pathologies associated with and in some cases potentially contributing to AD pathology.
These are novel, previously undescribed lipid biomarkers for AD and holdout diagnostic promise
for patients with AD, including early stage disease. As such, they should help in identifying
individuals with early AD events and provide a tool for easier and more rational selection of
subjects for trials of potential AD therapies.

159

4.6 References
1. Schneider, J. A.; Arvanitakis, Z.; Bang, W.; Bennett, D. A., Mixed brain pathologies account
for most dementia cases in community-dwelling older persons. Neurology 2007, 69 (24), 21972204.
2. Schneider, J. A.; Aggarwal, N. T.; Barnes, L.; Boyle, P.; Bennett, D. A., The neuropathology of
older persons with and without dementia from community versus clinic cohorts. J.Alzheimer's Dis.
2009, 18 (3), 691.
3. Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.;
Hasegawa, K.; Hendrie, H.; Huang, Y., Global prevalence of dementia: a Delphi consensus study.
The lancet 2006, 366 (9503), 2112-2117.
4. Hardy, J., The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J. Neurochem.
2009, 110 (4), 1129-1134.
5. Maccioni, R. B.; Muñoz, J. P.; Barbeito, L., The molecular bases of Alzheimer's disease and
other neurodegenerative disorders. Archives of medical research 2001, 32 (5), 367-381.
6. Jack, C.; Petersen, R. C.; Xu, Y. C.; O’Brien, P. C.; Smith, G. E.; Ivnik, R. J.; Boeve, B. F.;
Waring, S. C.; Tangalos, E. G.; Kokmen, E., Prediction of AD with MRI-based hippocampal
volume in mild cognitive impairment. Neurology 1999, 52 (7), 1397-1397.
7. Hampel, H.; Bürger, K.; Teipel, S. J.; Bokde, A. L.; Zetterberg, H.; Blennow, K., Core candidate
neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimer's & Demen.2008, 4 (1),
38-48.
8. Jack, C. R.; Lowe, V. J.; Senjem, M. L.; Weigand, S. D.; Kemp, B. J.; Shiung, M. M.; Knopman,
D. S.; Boeve, B. F.; Klunk, W. E.; Mathis, C. A., 11C PiB and structural MRI provide
complementary information in imaging of Alzheimer's disease and amnestic mild cognitive
impairment. Brain 2008, 131 (3), 665-680.
9. Forsberg, A.; Engler, H.; Almkvist, O.; Blomquist, G.; Hagman, G.; Wall, A.; Ringheim, A.;
Långström, B.; Nordberg, A., PET imaging of amyloid deposition in patients with mild cognitive
impairment. Neurobiol. Aging 2008, 29 (10), 1456-1465.
10. Wall, A.; Chiotis, K.; Saint-Aubert, L.; Wilking, H.; Sprycha, M.; Borg, B.; Thibblin, A.;
Eriksson, J. P.; Sörensen, J.; Antoni, G., Tracer kinetic analysis of (S)-18F-THK5117 as a PET
tracer for assessing tau pathology. J. Nuclear Med. 2016, jnumed. 115.158519.
11. Samuraki, M.; Matsunari, I.; Chen, W.-P.; Yajima, K.; Yanase, D.; Fujikawa, A.; Takeda, N.;
Nishimura, S.; Matsuda, H.; Yamada, M., Partial volume effect-corrected FDG PET and grey
matter volume loss in patients with mild Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging
2007, 34 (10), 1658-1669.
160

12. Panegyres, P. K.; Rogers, J. M.; McCarthy, M.; Campbell, A.; Wu, J. S., Fluorodeoxyglucosepositron emission tomography in the differential diagnosis of early-onset dementia: a prospective,
community-based study. BMC Neurol. 2009, 9 (1), 41.
13. Tang, B. L.; Kumar, R., Biomarkers of mild cognitive impairment and Alzheimer's disease.
Ann. Acad. Med. Singapore 2008, 37 (5), 406-5.
14. Mayeux, R.; Honig, L.; Tang, M.-X.; Manly, J.; Stern, Y.; Schupf, N.; Mehta, P., Plasma Aβ40
and Aβ42 and Alzheimer’s disease Relation to age, mortality, and risk. Neurology 2003, 61 (9),
1185-1190.
15. Fukumoto, H.; Tennis, M.; Locascio, J. J.; Hyman, B. T.; Growdon, J. H.; Irizarry, M. C., Age
but not diagnosis is the main predictor of plasma amyloid β-protein levels. Archives of neurology
2003, 60 (7), 958-964.
16. Irizarry, M. C., Biomarkers of Alzheimer disease in plasma. NeuroRx 2004, 1 (2), 226-234.
17. Patterson, C.; Feightner, J. W.; Garcia, A.; Hsiung, G.-Y. R.; MacKnight, C.; Sadovnick, A.
D., Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer
disease. Can. Med. Assoc. J. 2008, 178 (5), 548-556.
18. Watson, A. D., Thematic review series: systems biology approaches to metabolic and
cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J.
Lipid Res. 2006, 47 (10), 2101-2111.
19. Klein, J., Membrane breakdown in acute and chronic neurodegeneration: focus on cholinecontaining phospholipids. J. Neural Transm. 2000, 107 (8-9), 1027-1063.
20.
Huang, X.; Moir, R. D.; Tanzi, R. E.; Bush, A. I.; Rogers, J. T., Redox‐Active Metals,
Oxidative Stress, and Alzheimer's Disease Pathology. Ann. N.Y.Acad. Sci. 2004, 1012 (1), 153163.
21.
Butterfield, D. A.; Perluigi, M.; Sultana, R., Oxidative stress in Alzheimer's disease brain:
new insights from redox proteomics. Eur. J.Pharmacol. 2006, 545 (1), 39-50.
22.
Praticò, D., The neurobiology of isoprostanes and Alzheimer's disease. Biochimica et
Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 2010, 1801 (8), 930-933.
23.
Bet, L.; Calabrese, E.; Bava, L.; Magni, E.; Rapuzzi, S.; Pezzoli, G.; Mariani, C.,
Malondialdheyde production features in platelets of Parkinson and Alzheimer patients and in
physiological aging. Neurosci. Res. Commun. 1999, 25 (1), 33-41.
24.
Svennerholm, L.; Gottfries, C. G., Membrane Lipids, Selectively Diminished in Alzheimer
Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination
in Late‐Onset Form (Type II). J. Neurochem. 1994, 62 (3), 1039-1047.

161

25.
Han, X.; M Holtzman, D.; W McKeel, D.; Kelley, J.; Morris, J. C., Substantial sulfatide
deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease
pathogenesis. J. Neurochem. 2002, 82 (4), 809-818.
26.
Cutler, R. G.; Kelly, J.; Storie, K.; Pedersen, W. A.; Tammara, A.; Hatanpaa, K.; Troncoso,
J. C.; Mattson, M. P., Involvement of oxidative stress-induced abnormalities in ceramide and
cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2004,
101 (7), 2070-2075.
27.
Harrell, F. E.; Lee, K. L.; Mark, D. B., Tutorial in biostatistics multivariable prognostic
models: issues in developing models, evaluating assumptions and adequacy, and measuring and
reducing errors. Stat. Med. 1996, 15, 361-387.
28.
Efron, B.; Tibshirani, R., Improvements on cross-validation: the 632+ bootstrap method.
JASA 1997, 92 (438), 548-560.
Touboul, D.; Roy, S.; Germain, D. P.; Chaminade, P.; Brunelle, A.; Laprévote, O.,
29.
MALDI-TOF and cluster-TOF-SIMS imaging of Fabry disease biomarkers. Int. J. Mass Spectr.
2007, 260 (2), 158-165.
30.
Chughtai, K.; Jiang, L.; Greenwood, T. R.; Glunde, K.; Heeren, R. M., Mass spectrometry
images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor
models. J. Lipid Res. 2013, 54 (2), 333-344.
31.
Hsu, F.-F.; Turk, J., Electrospray ionization with low-energy collisionally activated
dissociation tandem mass spectrometry of glycerophospholipids: mechanisms of fragmentation
and structural characterization. J. Chromatogr. B 2009, 877 (26), 2673-2695.
32.
Enomoto, H.; Sugiura, Y.; Setou, M.; Zaima, N., Visualization of phosphatidylcholine,
lysophosphatidylcholine and sphingomyelin in mouse tongue body by matrix-assisted laser
desorption/ionization imaging mass spectrometry. Anal. Bioanal. Chem. 2011, 400 (7), 19131921.
33.
Liebisch, G.; Binder, M.; Schifferer, R.; Langmann, T.; Schulz, B.; Schmitz, G., High
throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem
mass spectrometry (ESI-MS/MS). Biochimica et Biophysica Acta (BBA)-Molecular and Cell
Biology of Lipids 2006, 1761 (1), 121-128.
34.
Yu, S.; Dong, J.; Zhou, W.; Yang, R.; Li, H.; Zhao, H.; Zhang, T.; Guo, H.; Wang, S.;
Zhang, C., A rapid and precise method for quantification of fatty acids in human serum cholesteryl
esters by liquid chromatography and tandem mass spectrometry. J. Chromatogr. B 2014, 960, 222229.
35.
Berry, K. A. Z.; Murphy, R. C., Electrospray ionization tandem mass spectrometry of
glycerophosphoethanolamine plasmalogen phospholipids. J. Am. Soc. Mass Spectr. 2004, 15 (10),
1499-1508.

162

36.
Uchikata, T.; Matsubara, A.; Nishiumi, S.; Yoshida, M.; Fukusaki, E.; Bamba, T.,
Development of oxidized phosphatidylcholine isomer profiling method using supercritical fluid
chromatography/tandem mass spectrometry. J. Chromatogr. A 2012, 1250, 205-211.
37.
Byrdwell, W.; Neff, W. E., Dual parallel electrospray ionization and atmospheric pressure
chemical ionization mass spectrometry (MS), MS/MS and MS/MS/MS for the analysis of
triacylglycerols and triacylglycerol oxidation products. Rapid Commun. Mass Spectrom. 2002, 16
(4), 300-319.
38.
Zeb, A., Triacylglycerols composition, oxidation and oxidation compounds in camellia oil
using liquid chromatography–mass spectrometry. Chem. Phys. Lipids 2012, 165 (5), 608-614.
39.
Shah, D. J.; Rohlfing, F.; Anand, S.; Johnson, W. E.; Alvarez, M. T. B.; Cobell, J.; King,
J.; Young, S. A.; Kauwe, J. S.; Graves, S. W., Discovery and confirmation of novel serum
biomarkers diagnosing Alzheimer’s disease.
Wenk, M. R., The emerging field of lipidomics. Nat. Rev. Drug Discov. 2005, 4 (7), 59440.
610.
41.
Hu, C.; van der Heijden, R.; Wang, M.; van der Greef, J.; Hankemeier, T.; Xu, G.,
Analytical strategies in lipidomics and applications in disease biomarker discovery. J.
Chromatogr.B 2009, 877 (26), 2836-2846.
42.
Han, X.; Gross, R. W., Shotgun lipidomics: electrospray ionization mass spectrometric
analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples.
Mass Spectrom. Rev. 2005, 24 (3), 367-412.
Mangialasche, F.; Kivipelto, M.; Mecocci, P.; Rizzuto, D.; Palmer, K.; Winblad, B.;
43.
Fratiglioni, L., High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in
advanced age. J. Alzheimer's Dis.2010, 20 (4), 1029.
KONTUSH, A.; SCHEKATOLINA, S., Vitamin E in neurodegenerative disorders:
44.
Alzheimer's disease. Ann. N.Y. Ac.Sci. 2004, 1031 (1), 249-262.
45.
BAZAN, N. G.; de TURCO, E. B. R.; ALLAN, G., Mediators of injury in neurotrauma:
intracellular signal transduction and gene expression. J. Neurotrauma 1995, 12 (5), 791-814.
46.
Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.;
Eikelenboom, P.; Emmerling, M.; Fiebich, B. L., Inflammation and Alzheimer’s disease.
Neurobiol. Aging 2000, 21 (3), 383-421.
47.
260.

Heneka, M. T., Inflammation in Alzheimer’s disease. Clin. Neurosci. Res. 2006, 6 (5), 247-

48.
He, X.; Huang, Y.; Li, B.; Gong, C.-X.; Schuchman, E. H., Deregulation of sphingolipid
metabolism in Alzheimer's disease. Neurobiol. Aging 2010, 31 (3), 398-408.

163

49.
Merrill, A.; Schmelz, E.; Dillehay, D.; Spiegel, S.; Shayman, J.; Schroeder, J.; Riley, R.;
Voss, K.; Wang, E., Sphingolipids—the enigmatic lipid class: biochemistry, physiology, and
pathophysiology. Toxicol. Appl. Pharmacol.1997, 142 (1), 208-225.
50.
Ichi, I.; Nakahara, K.; Miyashita, Y.; Hidaka, A.; Kutsukake, S.; Inoue, K.; Maruyama, T.;
Miwa, Y.; Harada-Shiba, M.; Tsushima, M., Association of ceramides in human plasma with risk
factors of atherosclerosis. Lipids 2006, 41 (9), 859-863.
Rodríguez, J. J.; Jones, V. C.; Verkhratsky, A., Impaired cell proliferation in the
51.
subventricular zone in an Alzheimer's disease model. Neuroreport 2009, 20 (10), 907-912.
52.
Casserly, I.; Topol, E. J., Convergence of atherosclerosis and Alzheimer's disease:
inflammation, cholesterol, and misfolded proteins. The Lancet 2004, 363 (9415), 1139-1146.
53.
Han, X.; Holtzman, D. M.; McKeel, D. W., Plasmalogen deficiency in early Alzheimer's
disease subjects and in animal models: molecular characterization using electrospray ionization
mass spectrometry. J. Neurochem. 2001, 77 (4), 1168-1180.
54.
Ginsberg, L.; Rafique, S.; Xuereb, J. H.; Rapoport, S. I.; Gershfeld, N. L., Disease and
anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain
Res. 1995, 698 (1), 223-226.
55.
Ginsberg, L.; Xuereb, J. H.; Gershfeld, N. L., Membrane instability, plasmalogen content,
and Alzheimer's disease. J. Neurochem.1998, 70 (6), 2533-2538.
56.
Terry, R. D.; Masliah, E.; Salmon, D. P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L.
A.; Katzman, R., Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the
major correlate of cognitive impairment. Ann.Neurol. 1991, 30 (4), 572-580.
57.
Migliore, L.; Fontana, I.; Colognato, R.; Coppede, F.; Siciliano, G.; Murri, L., Searching
for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other
neurodegenerative diseases. Neurobiol. Aging 2005, 26 (5), 587-595.
58.
Sultana, R.; Mecocci, P.; Mangialasche, F.; Cecchetti, R.; Baglioni, M.; Butterfield, D. A.,
Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from
patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease
and initial investigations into a potential biomarker for this dementing disorder. J. Alzheimer's
Dis.: JAD 2010, 24 (1), 77-84.
59.
Song, F.; Poljak, A.; Smythe, G. A.; Sachdev, P., Plasma biomarkers for mild cognitive
impairment and Alzheimer's disease. Brain Res. Rev. 2009, 61 (2), 69-80.
60.
Burgess, B. L.; McIsaac, S. A.; Naus, K. E.; Chan, J. Y.; Tansley, G. H.; Yang, J.; Miao,
F.; Ross, C. J.; van Eck, M.; Hayden, M. R., Elevated plasma triglyceride levels precede amyloid
deposition in Alzheimer’s disease mouse models with abundant Aβ in plasma. Neurobiol. Dis.
2006, 24 (1), 114-127.

164

61.
Mapstone, M.; Cheema, A. K.; Fiandaca, M. S.; Zhong, X.; Mhyre, T. R.; MacArthur, L.
H.; Hall, W. J.; Fisher, S. G.; Peterson, D. R.; Haley, J. M., Plasma phospholipids identify
antecedent memory impairment in older adults. Nat. Med. 2014, 20 (4), 415-418.

165

Chapter 5

Concluding Remarks

5.1 Summary of Current Research Accomplishments

5.1.1 Summary of our PE proteomics research
A study involving sera from 24 controls, having term uncomplicated pregnancies and 24 cases,
who developed PE later in the same pregnancy was conducted using a novel serum proteomic
approach to detect low molecular weight biomarkers for PE. This study led to the detection of 66
species demonstrating statistical differences between the cases and the controls. Further statistical
analysis on these biomarkers resulted in production of panels having combinations of markers with
a higher sensitivity and specificity (AUC~0.99) as compared to individual markers. Chemical
structure characterization MS/MS studies were successfully performed on 19 biomarkers. Six of
these biomarkers were identified to be peptides based on the fragmentation pattern, while 13 were
found to be lipids belonging to the class of glycerophosphocholines or sphingomyelins. Multimarker panels were also developed using only the validated chemically characterized candidate
markers that demonstrated AUC of around 0.8. Developed panels of serum biomarkers appeared
effective in identifying pregnant women at 12–14 weeks gestation at risk of PE later in their
pregnancy.
5.1.2 Summary of our PE lipidomics research
A discovery study was performed using sera collected at 12-14 weeks pregnancy from 27 controls
with uncomplicated pregnancies and 29 cases that later developed PE in that pregnancy to find
lipid biomarkers for PE. Lipids were extracted from the serum samples using organic solvents and
were analyzed using direct infusion mass spectrometry. MS signals demonstrating statistical
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differences were selected. This study led to detection of 45 potential lipid biomarkers. These lipid
markers were reevaluated in a second confirmatory study having 43 controls and 37 preeclampsia
cases. Of the 45 biomarkers from the first study, 23 markers continued to be statistically significant
in the second confirmatory set. Most of these markers, representing several lipid classes, were
chemically characterized typically providing lipid class and putative chemical structures using
tandem MS. These preeclampsia biomarkers were found to belong to diverse lipid classes
including fatty acids, cholesteryl esters, phosphatidylcholines, lysophosphocholines, triglycerides
and sterols. Several multi-marker panels with AUC >0.85 and high predictive values were
developed from the 23 validated biomarkers. Developed panels of serum lipidomic biomarkers
appear able to identify most women at risk for preeclampsia in a given pregnancy at 12-14 weeks
gestation.

5.1.3 Summary of AD lipidomic project
A shotgun lipidomic approach was undertaken to determine if lipid biomarkers exist that can
discriminate AD cases (all stages) from controls. The discovery study involved sera from 29 any
stage AD cases and 32 age and gender matched controls. Lipid extraction was performed using
organic solvent and the samples were directly infused into a time-of-flight mass spectrometer.
Statistically significant lipid markers demonstrating differences between AD cases and controls
were detected. These potential lipid diagnostic biomarkers were reevaluated in a second
confirmatory study involving 27 cases and 30 controls. The initial study detected 89 potential AD
markers. Of these, 35 markers continued to be statistically significant in the second confirmatory
set. Tandem MS studies were performed and almost all of the confirmed markers were chemically
classified and characterized. Using the confirmed markers, several multi-marker panels with AUC
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> 0.87 were developed for any stage AD cases vs controls. Additionally, using confirmed
biomarkers, models were developed for individual stages of AD. Multi-marker panels with AUCs
> 0.90 were developed for each specific CDR vs controls, including the earliest stage of AD. These
lipidomic biomarkers are likely to distinguish AD cases from controls at any stage.

5.2 Limitations of our current research
5.2.1 Limitations of our PE proteomics research
Although this study provided many statistically significant potential biomarkers, some limitations
need to be mentioned. This study was initially started with the purpose of detecting low M.W.
peptides as biomarkers for PE. However, when tandem MS studies were performed on potential
biomarkers, several markers were identified to belong to a lipid class of glycerophosphocholines.
Several other markers remained unidentified probably belonging to some other class of
metabolites. There were a number of markers which could not be fragmented due to lack of sample
availability.
The micro capillary column used for peptide separation was packed with POROS R1 slurry having
a particle size of 10 µm. This resulted in broader, less resolved and overlapping peaks complicating
the quality of data and making the analysis at times difficult.
Although desirable, a validation study having a large set of PE cases and controls could not be
carried out to re-evaluate the performance of detected potential biomarkers due to unavailability
of serum samples. Such large prospective pregnancy studies are very few and none to our
knowledge have also sampled women at 12-14 weeks gestation. Consequently, either later
gestational time points might be studied in existing pregnancy if access to sera could be obtained
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or the NIH would need to initiate a new prospective study that included these very early gestation
age samples being collected.
5.2.2 Limitations of our PE lipidomics project
This study, involving direct infusion of lipid extracts into a TOF mass spectrometer provided
several potential lipid biomarkers which in combination resulted in good predictive values. Some
issues still need to be addressed.

Shotgun lipidomics using direct infusions mass spectrometry has an advantage of smaller run times
leading to higher sample throughput and faster analysis. However, for comprehensive analysis of
lipids, LC/MS is still preferred as it would result in 5 fold more MS variables or features being
observable1. Also, separation of isobaric peaks is not always obtained in direct infusion mass
spectrometry. Therefore, lipids having the same or very similar molecular masses belonging to
either the same or different lipid classes are not always separated by direct infusion techniques
using a TOF-MS.

Direct infusion also results in ion suppression due to so many different ionization efficiencies of
lipids from diverse classes being introduced simultaneously. Although normalization strategies
help, they do not eliminate the problem.

The reproducibility of the runs is also quite variable with directly infused samples as the sensitivity
of the instrument varies for incompletely understood reasons (e.g. residual solvent) or the amount
of specimen introduced varies due to clogging of the ESI needle and there are other sources of
instrument or ionization variations.
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Unlike proteomics studies, there are no biological assays to quantitate total lipids in human
specimens. Similar to other lipid researchers, we also used the equal volume of different samples
and infused it into mass spectrometer without knowing if total lipid concentration varied. This
could lead to variability in peak height as the total lipid concentration may vary from person to
person or from extraction to extraction.
5.2.3 Limitations of AD lipidomic project
Many of the analytical concerns here are identical to those described in the PE lipidomic study.
Additionally, many AD cases detected with CDR of 0.5, 1 and 2 might be on some prescribed
medications. This is typically an aged population with many co-morbities. These medications may
have altered some biomarkers or produced artifacts in the study.

This study was carried out on a particular population group with limited numbers of cases and
controls. It would be useful to carry out the study on populations from different parts of world as
these biomarkers might be altered in other populations with or without disease.

The cases included small numbers of patients with CDR 0.5, 1 and 2. A greater set of patients each
with CDR 0.5, 1 and 2 would allow us to compare the levels of these biomarkers with severity of
the disease and have greater confidence in the markers found and may also allow us to discover
and validate markers specific to a particular stage of disease.

5.3 Future objectives
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5.3.1 Future research objectives of the PE proteomics study
This study appears promising with many novel candidate serum biomarkers discovered and many
effective combinations developed providing potentially valuable risk assessment of PE. Future
studies will need to retest and validate these candidate markers in independent specimens from
different populations with laboratory analysis carried out without knowledge of case or control
status. This will require accumulation of or access to similarly timed specimens, processed
expeditiously to allow for similar results and not submitted to freeze thaw cycles, which degrade
proteins. If the markers are shown to be valid over time and considered useful in the screening of
pregnant women, the MS method could be scaled up (as was done for the preterm labor marker
fetal fibronectin2 to analyze high numbers of specimens at a reference laboratory. Alternatively,
individual high throughput assays, for example, immunoassays, may be developed for several of
the best markers as has been done for other clinical assay panels (lipids, cardiovascular risk factors,
and so on). Also, these markers themselves suggest biochemical changes occurring early in the
pregnancies of women who will develop PE many weeks later. Further studies of these suggested
pathways or processes, for example, ROS, would be helpful in more fully explaining or verifying
very early pathologic changes leading to PE. Having useful, verified biomarkers that predict later
PE would allow for far smaller clinical studies, including evaluation of pharmacologic or other
medical treatments for this potentially fatal disease.
5.3.2 Future research objective of PE lipidomics study
Although, we carried out an initial discovery study and a validation study which resulted in 23 out
of 45 lipid markers being validated, several future studies could be proposed.
Numerous validation studies including larger sets of PE cases and controls from different parts of
the world should be carried out before clinical assays could be developed for these markers.
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This study was carried out in the positive ion mode. Similar studies in the future involving samples
run in the negative ion mode will allow us to detect anionic and weakly anionic lipids.

Studies involving treatment of placental cells with synthetic standards of the individual lipid
markers might provide some insights into the biological activity or roles of individual lipid
biomarkers in PE.

Quantitative studies should be carried out in the future by using known concentrations of the
internal standards of the validated lipid biomarkers to detect amounts of these markers in the
diseased patients. This would dramatically reduce pre-analytical and analytical variability and
allow the biological variability to be better established.
5.3.3 Future research objectives for our AD lipidomics study
In this study, the discovery set let to detection of 89 lipid biomarkers. In the confirmatory set 35
out of 89 markers were validated. Although, a confirmation study was performed, it is well
recognized that replication of the results from this study needs to be performed in other larger and
more diverse sets of populations. It would also be of interest to monitor changes in serum
biomarkers over time in order to study the stability of the lipid markers. Further, given the
alterations in lipids in response to AD, it would be useful to more directly study possible biologic
roles for some of the individual molecular species of lipids in the context of AD.
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